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The two studies of this thesis ought to gain a deeper understanding of the pathomechanisms 
underlying schizophrenia and bipolar disorder. Even though a great amount of research 
revealed structural or functional alterations in both disorders, none of the previous results has 
matured into a clinically applicable biomarker, yet. This is due to the fact that most psychiatric 
disorders have complex and diverse origins as well as individual forms of progression. This 
thesis was driven by the possibility of finding specific neurobiological markers that might 
reliably be ascribed to the disorders or subgroups. Furthermore, the ability to predict treatment 
response or improve the status quo of current treatment through analyses of neuroimaging 
data would have great advances on the course of the diseases. 
1.1   Overview disorders 
The first chapter is supposed to give a summary of the two psychiatric disorders involved in the 
two different studies of this thesis. The manifestation and hypotheses around the development 
of schizophrenia and bipolar disorder will be shortly described to better understand the 
subsequent description of impairments and deficits involved in the reward and attention 
networks of both disorders.  
1.1.1    Schizophrenia 
1.1.1.1    Symptoms & diagnosis 
Schizophrenia is characterized by impaired perception and thought disorder. Core symptoms 
listed in the International Statistical Classification of Diseases and Related Health Problems 
(ICD-10) are thought echo, thought insertion, delusions and hallucinations. Furthermore, so 
called negative symptoms can derogate the individual’s cognitive function temporarily, but also 
continue during euthymic phases. These include for example a lack of motivation, anhedonia 
and social withdrawal. In addition, schizophrenia patients suffer from cognitive impairment, 
such as shorter attention spans, longer reaction times and poorer performance during memory 
tasks (reviewed in Bowie and Harvey, 2005; reviewed in Heinrichs and Zakzanis, 1998; reviewed 
in Mesholam-Gately et al., 2009). Whereas the positive symptoms can be treated very well, 
cognitive dysfunctions often continue during remitted phases (Caldiroli et al., 2016; Kumar et 
al., 2016; Trivedi et al., 2007). Cognitive decline has sometimes also been defined as a hallmark 
of the disorder as it often appears many years before the actual onset of psychosis (Fuller et 
al., 2002; Reichenberg et al., 2010; van Oel et al., 2002). Kraepelin (1893) already described 
intellectual and cognitive disturbances more in-depth than positive symptoms such as 
hallucinations, delusions etc. (reviewed in van Os and Kapur, 2009). Moreover, schizophrenia 
was originally named dementia praecox (Bleuler, 1950; Morel, 1860, p.565-566). This 





in schizophrenia. Overall, schizophrenia is a severe psychiatric disorder with numerous 
symptoms of different dimensions that need to be addressed. This thesis will focus especially 
on potential deficits of schizophrenia patients in reward and cognitive control processes.  
1.1.1.2    Epidemiology & risk factors 
In general, the median lifetime prevalence of schizophrenia is stated with 0.4-0.87% and an 
incidence rate of 15 persons per 100’000 per year (reviewed in Kahn et al., 2015; reviewed in 
McGrath et al., 2008; reviewed in McGrath et al., 2004; reviewed in Saha et al., 2005). Taking 
related psychotic disorders such as e.g. schizoaffective disorders, delusional disorder etc. into 
account the prevalence rises to over three percent (Perala et al., 2007). Women and men are 
equally often affected; however, the incidence rate ratio median of men is higher than in 
women (1.4:1) (reviewed in Kahn et al., 2015; reviewed in McGrath et al., 2004). The disease 
onset is in the early adolescence, i.e. 16-30 years (reviewed in Owen et al., 2016). A systematic 
review of studies regarding clinical outcome and social recovery criteria found that the median 
recovery estimates of schizophrenia patients was only 13.5% (reviewed in Jääskeläinen et al., 
2013; reviewed in Kahn et al., 2015). Even worse, people suffering from schizophrenia have a 
significantly decreased life expectancy, i.e. 20 years below the general population and an 
increased excess mortality with 13.9% accounting for suicide (Charlson et al., 2015; reviewed 
in Laursen et al., 2014; Laursen et al., 2013; Lawrence et al., 2013). Moreover, early death is 
also caused by cardiovascular diseases which in many cases result from widespread cigarette 
abuse, a higher probability of living an unhealthy lifestyle or adverse effects of antipsychotic 
drugs leading to obesity (Bobes et al., 2010; Daumit et al., 2008; Jerrell et al., 2010; Kahn et al., 
2008; reviewed in Kahn et al., 2015; reviewed in Laursen et al., 2014). 
A lot of studies have been conducted to find causes of or risk factors for the development of 
schizophrenia. Pre-/ perinatal complications (reviewed in Cannon et al., 2002), life events 
(reviewed in Beards et al., 2013; Raune et al., 2009; reviewed in Varese et al., 2012), paternal 
age (Malaspina et al., 2001; Petersen et al., 2011), sex (reviewed in Aleman et al., 2003), 
urbanicity (Kirkbride et al., 2007; Pedersen and Mortensen, 2001) and migration (Hutchinson 
et al., 1996) have been described as possible risk factors for the onset of schizophrenia 
(reviewed in Kahn et al., 2015; reviewed in Owen et al., 2016). In addition, over the last 50 years 
the impact of genetics on the development of schizophrenia has also been examined. So far, 
the influence of genetics on schizophrenia has been found to be highly polygenic and 
pleiotropic making it impossible to predict its genesis (Gottesman and Shields, 1972; Lee et al., 
2013; reviewed in Owen et al., 2016). In sum, most likely a combination of environmental and 





1.1.1.3    Pathology 
For many years a lot of approaches in understanding the causes for schizophrenia have been 
ensued. Thereby, hypotheses which were developed on the basis of post-mortem studies, 
genetic factors, neurodevelopmental influences and structural or functional imaging, have tried 
to fathom the core pathophysiology of schizophrenia (reviewed in Kahn et al., 2015). 
Experiments examining the brain tissue of deceased schizophrenia patients have found 
multiple cellular abnormalities regarding receptors involved in dopaminergic, glutamatergic 
and gamma-Aminobutyric acid (GABA) transmission. Kestler et al. conducted a meta-analysis 
and reported increased dopamine receptor density in schizophrenia patients (reviewed in 
Kestler et al., 2001). Furthermore, morphological variations of glutamatergic neuron dendrites 
were reviewed by Hu et al. (2015). Consistently, hypofunction of GABAergic transmission 
resulting from plausible molecular and cellular alterations was reported (reviewed in Curley 
and Lewis, 2012; Guillozet-Bongaarts et al., 2014). Moreover, relative and twin studies as well 
as genome wide association studies have shed some light on genetic factors and risk loci that 
seem to be involved in the development of schizophrenia (reviewed in Cardno and Gottesman, 
2000; Ripke et al., 2014). However, their molecular implications have not been completely 
understood, yet. Further experiments tried to link neurodevelopmental factors to the genesis 
of schizophrenia and found repeatedly associated genes that are mostly expressed during fetal 
brain development (Birnbaum et al., 2014; Gulsuner et al., 2013; Jaffe et al., 2015). Although a 
broad spectrum of hypotheses with several approaches has been tested so far, it can be 
concluded that multiple factors influence the genesis, course and outcome of schizophrenia. 
The most accepted and wide-spread theory regarding the psychopathology of schizophrenia is 
the dopamine hypothesis (reviewed in Baumeister and Francis, 2002; reviewed in Grace, 2016; 
reviewed in McCutcheon et al., 2019). It describes a strong involvement of dopamine 
dysfunctions due to excess or deficiencies at dopamine receptors sites. The dopamine 
hypothesis evolved when clinical studies reported a link between the administration of 
dopaminergic agonists or stimulants and the development of psychotic conditions in healthy 
individuals (Angrist and Gershon, 1970; Connell, 1957). Another great advance was 1975, when 
Seeman and Lee discovered that there was a direct relation between clinically potent dosages 
of antipsychotic drugs and the release of dopamine (Seeman and Lee, 1975). Soon after, post-
mortem studies elaborated enhanced levels of dopaminergic receptors in the striatum of 
schizophrenia patients (Lee and Seeman, 1980). Later, the development of positron emission 
tomography (PET) and single-photon emission computed tomography (SPECT) enabled in vivo 
examinations of the molecular underpinnings of the dopaminergic system in schizophrenia 
individuals (reviewed in McCutcheon et al., 2019). Experiments in the subsequent years 
revealed various factors such as elevated presynaptic dopaminergic function or the correlation 





that abnormalities in the dopaminergic system might contribute to psychotic conditions (Abi-
Dargham et al., 2009; Howes et al., 2013). The role of dopamine was extended to the aberrant 
salience hypothesis. It claims that an enhanced dopamine distribution leads to aberrant 
attribution of salience to external and internal stimuli before the actual outbreak of psychotic 
symtpoms (reviewed in Kapur, 2003). Over the years, however, conflicting results (among other 
things from genome-wide association studies) led to growing doubts concerning the dopamine 
hypothesis or, more precisely, the exclusive role of dopamine in the development of 
schizophrenia (Edwards et al., 2016; reviewed in Kambeitz et al., 2014). These concerns began 
to leave room for alternative hypotheses such as the exploration of neurodevelopmental 
factors or the involvement of other neurotransmitters (Sørensen et al., 2010; reviewed in Stahl, 
2018).  
Other neurotransmitters that have been associated with schizophrenia are serotonin and 
glutamate (reviewed in Stahl, 2018). As lysergic acid diethylamide (LSD) and psilocybin can 
induce hallucinations by acting as serotonin agonists, serotonin was thought to be involved in 
eliciting psychotic symptoms (Hoch et al., 1952; Hyde et al., 1978; Shaw and Woolley, 1956; 
Vollenweider et al., 1998). The association between serotonergic neurotransmission and 
positive symptoms had a strong impact on the following development of new 
psychopharmacological treatments, i.e. atypical antipsychotics (reviewed in Lally and MacCabe, 
2015; reviewed in Lieberman, 2004). As they act as partial agonists on dopaminergic and 
serotonergic receptors, they do not exclusively affect the dopaminergic system (Bymaster et 
al., 1996; Leysen et al., 1988; Saller and Salama, 1993). 
The findings of decreased glutamate levels in the cerebrospinal fluid of schizophrenia and the 
occurrence of psychotic symptoms after administration of N-methyl-D-aspartate (NMDA) 
receptor antagonists suggests that glutamate might be implicated in the development or 
continuity of schizophrenia (Fine and Finestone, 1973; reviewed in Hu et al., 2015; Kim et al., 
1980; Perel and Davidson, 1976). Glutamate is the key player in excitatory neurotransmission 
and binds to the NMDA receptor, which is important for learning and memory. The discovery 
of NMDA receptor alterations or abnormal expression supports the idea of dysfunctional 
glutamatergic neurotransmission (reviewed in Gao et al., 2000; Meador-Woodruff and Healy, 
2000). As potential treatment target, glutamate modulation might hence improve negative and 
cognitive symptoms in schizophrenia patients.   
Taken together it is not yet clear to which extent the different neurotransmitters contribute to 
the development and dimension of schizophrenia. Therefore, it is of great interest to better 





1.1.2    Bipolar disorder 
1.1.2.1    Symptoms 
According to the ICD-10, bipolar affective disorder is defined as a disorder consisting of at least 
two episodes of drastically altered mood in two opposite directions. On the one hand, states of 
mania or hypomania, i.e. severely enhanced energy and activity, and on the other hand, 
conditions of depression, i.e. strongly reduced levels of energy and activity, have to appear. 
Hypomanic or manic phases are often characterized by elevated mood, volubility, productivity 
and performance as well as decreased need for sleep. In more severe cases patients may 
present sexual disinhibition, irritability and importunity up to megalomania, delusions and 
hallucinations. During depressive episodes patients show a lack of energy, joy, concentration 
and appetite as well as rumination and feelings of guilt and worthlessness. In worse cases, 
patients vegetate and suffer from emotional numbness and suicidal thoughts. One or more 
manic episodes are the key criterion for meeting the diagnosis bipolar disorder II or I, 
respectively (reviewed in Vieta et al., 2018).  
Another major factor affecting bipolar patients is a decrease in cognitive performance (Basso 
et al., 2002; reviewed in Bora and Pantelis, 2015; reviewed in Cipriani et al., 2017; Martinez-
Aran et al., 2004). An integral amount of patients suffer from mild to severe disturbances in 
executive function, attention, reaction time and verbal as well as visual memory- not just during 
acute phases, but also in remission (reviewed in Altshuler et al., 2004; Cavanagh et al., 2002; 
Cullen et al., 2016; Daban et al., 2012; Eric et al., 2013; Mur et al., 2007; Sparding et al., 2015). 
Potential impairments in the cognitive control of attentional processes and its underlying 
neural networks will be investigated in this thesis. 
1.1.2.2    Epidemiology & risk factors 
In a broad study, Merikangas et al. (2011) conducted structured psychiatric diagnostic 
interviews (World Health Organization Composite International Diagnostic Interview) with 
more than 60’000 adults from America, Europe and Asia. They concluded a lifetime prevalence 
for bipolar I disorder of 0.6% and bipolar II disorder of 0.4%. In comparison, the epidemiological 
study by Blanco et al. (2017) with over 30’000 US-only adults reported a lifetime prevalence of 
2.1% in bipolar I disorder. A strict determination of age of onset is quite difficult; however, 
literature suggests a main age of onset in late adolescence up to the early forties (Merikangas 
et al., 2007). Approximately one-half to one-third of the bipolar patients will attempt suicide in 
their life leading to the highest suicide rate among affective disorders (Chen and Dilsaver, 1996; 
Valtonen et al., 2005). 
Over the years it has been discovered that bipolar disorder has a high heritability, i.e. 58-85% 





factors have been named to be associated with a greater risk of developing bipolar disorder 
(reviewed in Vieta et al., 2018). Reported influences have been caesarean section delivery 
(Chudal et al., 2014), smoking during pregnancy (Chudal et al., 2015; Talati et al., 2013), high 
paternal age (Frans et al., 2008) and adverse events in the childhood (reviewed in Bortolato et 
al., 2017; Jimenez et al., 2017).  
1.1.2.3    Pathology  
A multifactorial model consisting of a strong interdependency between environmental and 
genetic factors is the most convincing hypothesis regarding the pathology of bipolar disorder 
so far. Even if the heritability of bipolar disorder is reported to be up to 85% (McGuffin et al., 
2003), there is no single bipolar disorder-specific gene responsible for an outbreak of the 
disease (reviewed in Craddock and Sklar, 2013; reviewed in Vieta et al., 2018). In the recent 
years, genome-wide association studies (GWAS) proposed common variants, which partly have 
also been associated with schizophrenia (Hamshere et al., 2013; Sklar et al., 2011).  
It is anticipated that the interplay of different neurotransmitter systems, rather than a single 
one, is involved in the genesis of bipolar disorder. Beside the serotonergic and noradrenergic 
neurotransmitter systems, there are indications that a dysfunction or imbalance in the 
dopaminergic system might have a particular influence on this mood disorder (reviewed in 
Vieta et al., 2018). Around 40-50 years ago the dopamine hypothesis in bipolar disorder 
emerged within psychiatric research (reviewed in Ashok et al., 2017). It resulted from 
observations reporting similarities between manic behavior and the behavior after 
amphetamine consumption as well as findings of attenuating effects of anti-dopaminergic 
medication on mania (Jacobs and Silverstone, 1986; Nolen, 1983; Post et al., 1980). Initially, 
manic-like conditions were induced in rodents, e.g. hyperlocomotion, through different 
techniques such as amphetamine administration, dopamine transporter (DAT) knock-out, DAT 
blockers, dopamine receptor stimulation, etc. (Perry et al., 2009; Young et al., 2010). Results 
from these studies argue for an involvement of dopamine in bipolar disorder’s 
pathophysiology. More specifically, the results propose that hyperdopaminergia might induce 
manic-like behavior. Rodent studies showing a reversal of manic-like conditions through 
administration of mood stabilizers further support this hypothesis (Berggren et al., 1978; Gould 
et al., 2001; Shaldubina et al., 2002). Furthermore, a potential connection between 
hypodopaminergia and the initiation of depressive-like symptoms was shown by Winter et al. 
who described depressive-like behavior following lesions in dopaminergic regions, such as 
ventral tegmental area (VTA) and substantia nigra (Winter et al., 2007). However, the transition 






Whereas animal studies propose a quite straight-forward mechanism of hyperdopaminergia 
being responsible for manic symptoms and hypodopaminergia causing depressive symptoms, 
human (neuro-) imaging and post-mortem studies suffer from stringent and consistent 
explanations of bipolar disorder symptomatology. This is due to the fact that, on the one hand, 
a lot of studies report contradicting results and, on the other hand, most of the studies have 
not been replicated (reviewed in Ashok et al., 2017; Kaalund et al., 2014; Pantazopoulos et al., 
2004). Therefore, the current literature yields indications of abnormalities of reward-related 
activity in bipolar disorder but cannot clearly propose the underlying molecular pathways. 
Many results showed an increase or upregulation of dopamine receptors and transporters or 
vesicular monoamine transporter protein (VMAT-2), which is involved in the storage of 
dopamine (Kaalund et al., 2014; Pearlson et al., 1995; Wong et al., 1997; Zhan et al., 2011; 
Zubieta et al., 2000). Neuroimaging data suggests abnormal reward-related activity in the 
nucleus accumbens (NAc), striatum and frontal cortex (Bermpohl et al., 2010; Mason et al., 
2014; Nusslock et al., 2012; Trost et al., 2014).  
In addition to potential imbalances of neurotransmitter systems, factors such as altered 
endocrine function (in particular regarding the hypothalamic–pituitary–adrenal (HPA) axis) and 
modulation of synaptic plasticity as well as alterations in cellular and molecular connectivity 
have been discussed (Grande et al., 2010; reviewed in Vieta et al., 2018; Vieta et al., 1999). In 
the last years, a lot of research focused on parameters such as neurotrophic molecules, 
dendritic spines, which have a huge impact on synaptic and neural plasticity, oxidative stress, 
mitochondria and inflammation (Andreazza et al., 2009; Cunha et al., 2006; Grande et al., 2014; 
Konopaske et al., 2014; Rao et al., 2010). Taken together, intertwined influences of various 
pathomechanisms seem to affect the phenotype of bipolar disorder and further experiments 
need to validate the current hypotheses. 
1.1.3    Treatment 
1.1.3.1    Psychopharmacology 
The most commonly applied psychopharmacological treatment of schizophrenia is the 
administration of atypical antipsychotics, such as olanzapine, risperidone, quetiapine etc. (Toto 
et al., 2019). Although most bipolar patients received lithium or anticonvulsant compounds as 
treatment of choice, since the beginning of the 21st century atypical antipsychotics have also 
gained ground in the treatment of mania. When multiple studies reported their antimanic 
effects, the USA Food and Drug Administration (FDA) approved several atypical antipsychotics 
as psychopharmacological treatment option for bipolar disorder (Keck et al., 2003a; Keck et al., 
2003b; Tohen et al., 2000). Second-generation antipsychotics share their mode of action, i.e. 
they influence dopaminergic as well as serotonergic receptors (Bymaster et al., 1996; Leysen 





affect dopaminergic receptors (Seeman et al., 1975). Their oftentimes strong side effects, in 
particular extrapyramidal symptoms which cause motor malfunction, led to the development 
of atypical antipsychotics (reviewed in Lally and MacCabe, 2015).  
One special atypical antipsychotic is aripiprazole, also called third-generation antipsychotic. Its 
mechanism of action differs from the second-generation antipsychotics by acting as partial 
agonist at the dopamine D2 receptor and serotonin (5-HT(1A)) receptors (Burris et al., 2002; 
Jordan et al., 2002). Its unique profile has been shown to achieve as high clinical efficacy as 
other atypical antipsychotics, while at the same time demonstrating very low side effects (Kane 
et al., 2002; reviewed in Leucht et al., 2013). Partial agonists act as functional agonists in 
surroundings where no dopamine is present and thereby initiate a, however attenuated, 
response (Momiyama et al., 1996). In addition, aripiprazole can also operate as functional 
antagonists in the presence of dopamine (Inoue et al., 1996; Kikuchi et al., 1995; Semba et al., 
1995). In this case it prevents dopaminergic binding and decreases the overall effect. Third-
generation antipsychotics seem to offer a great mode of action, as increased dopaminergic 
transmission in the mesolimbic pathway might be responsible for positive symptoms and 
decreased distribution in the mesocortical pathway might be associated with negative 
symptoms and cognitive impairment (reviewed in McCutcheon et al., 2019; reviewed in Patel 
et al., 2014). Due to their balancing effects they can fulfill both requirements.  
In one of the two studies conducted in this thesis, patients will be subdivided into response 
arms of atypical, typical and aripiprazole treatment. It was of interest to investigate if patients 
(not) responding to the respective treatments show differences in their brain activation during 
a reward-related paradigm.  
1.1.3.2    Treatment response prediction 
Multivariate methods, i.e. pattern-classifiers as predictors of variables were developed for the 
first time for PET data in the beginning of the 1990s (Azari et al., 1993; Clark et al., 1991; 
Kippenhan et al., 1992; Moeller and Strother, 1991; reviewed in O'Toole et al., 2007).  
Classifiers are functions that use various parameters of an example to predict the class of the 
respective example. Thereby, the classifier learns specific features of the examples from 
training data. It develops a model of the relationship between features and class, which is then 
able to predict the classes of new examples from a test set. The most important underlying 
assumption for this type of analysis is the random splitting of training and test data from an 
example distribution (reviewed in Pereira et al., 2009).  
In the case of small samples, the application of leave-one-out cross-validation offers the 





with a by one example reduced data set and validated with the remaining data sample n times 
until every example was left out (reviewed in Pereira et al., 2009). 
Up to now, only few studies have used support vector machine (SVM) algorithms on functional 
magnetic resonance imaging (fMRI) data of psychiatric disorders to predict treatment response 
of psychopharmacological treatment. However, there is one study by Mansson et al. (2015) 
who applied supervised SVM analyses to predict the long-term outcome of web-based 
cognitive behavioral therapy (CBT). They included blood oxygen level dependent (BOLD) 
responses from the dorsal anterior cingulate cortex and amygdala to predict long-term 
response rates and were able to reach 92% accuracy. Another study from Mechelli et al. (2017) 
tried to predict clinical outcomes and functioning of people at ultra-high risk for psychosis. In 
this case they used psychopathological information, i.e. scores of different rating scales, to 
forecast the longitudinal development of their subjects. The prediction of transition to 
psychosis reached an accuracy of 64.6% and the functioning 62.5%. A study from Fleck et al. 
(2017) used a cascading genetic fuzzy tree design to develop a linguistic machine learning 
system which should predict the treatment response of bipolar patients to lithium. As inputs 
they fed the algorithm 1H-MRS and fMRI data. Their machine learning system was able to 
predict post-treatment symptom reduction with 88% accuracy. Furthermore, in a clinical trial 
the efficacy of repetitive transcranial magnetic stimulation in schizophrenia patients was 
predicted with the help of machine learning algorithms. By employing structural magnetic 
resonance images, they achieved a cross-validated balanced accuracy of 85% for the response 
prediction (Koutsouleris et al., 2018).  
In sum, there is a slowly emerging field of treatment response prediction studies. Due to the 
very heterogeneous responses to antipsychotic treatment and the lack of prediction 
parameters, most patients are currently treated according to a trial-and-error principle 
(reviewed in Lally and MacCabe, 2015). This, in turn, results in longer acute phases of disease 
and thus suffering of psychiatric patients. Therefore, it is of great relevance and importance to 
further explore this field and make use of SVM algorithms to potentially predict treatment 
response in the future.   
1.2   Overview brain networks 
In the following chapter, the underlying neural networks of reward and attention will be closely 
examined in general and in the psychopathological context. The two paradigms described in 
this thesis strongly rely on these networks. Presenting the current state of knowledge about 
the reward circuit in general and attentional effects will hence help to interpret the results of 





1.2.1    Reward processing 
1.2.1.1    Reward circuit of the human brain 
Reward processing comprises many elements such as assessment of reward outcome 
probability, prediction error, goal-directed behavior and positive reinforcement for learning. 
Apart from that, primary and secondary rewards can be defined. Primary rewards comprise 
pleasant tastes, sounds etc., whereas secondary rewards describe monetary gains etc. In 
addition, reward processing can also be divided into reward anticipation and response to 
reward outcome (reviewed in Haber and Knutson, 2010).    
The brain region most often associated with reward is the ventral striatum, consisting of the 
NAc, ventral medial caudate and rostroventral putamen. They receive input from the medial 
prefrontal cortex (PFC), orbitofrontal cortex (OFC), dorsal anterior cingulate cortex, VTA, 
amygdala and hippocampus. The ventral striatum projects to the ventral pallidum and midbrain 
which relays further back to the PFC. This interacting network is called the frontostriatal neural 
circuit. An important feature of this circuit is the massive reciprocal influences of the ventral 
striatum and midbrain. On the one hand, striatal projections together with projections from 
the ventral pallidum arrive at the VTA and substantia nigra pars compacta. On the other hand, 
dopaminergic projections from dopamine neurons of the VTA and substantia nigra pars 
compacta project back to the ventral striatum (reviewed in Haber and Knutson, 2010). Three 
major dopaminergic projections define the reward circuit: the mesolimbic (VTA to NAc), 
mesocortical (VTA to PFC) and nigrostriatal (substantia nigra to putamen and caudate nucleus) 
(reviewed in Björklund and Dunnett, 2007).  
Specific brain regions were attributed to the reward circuit for the first time in a rodent 
experiment by Milner and Olds (1954). They implanted a number of electrodes in various 
regions of the rats’ brains and prepared a setup in which the rats could reward themselves via 
button press. The results showed the greatest electrical stimulation in septal regions. Later, 
electrophysiological experiments in primates demonstrated phasic discharges of action 
potentials in dopaminergic neurons following unanticipated food reward during an operant 
condition task (Ljungberg et al., 1992). In the following, the reward prediction error (RPE) 
hypothesis was proposed, stating that dopaminergic neurons code the difference between 
anticipated reward and its effective outcome (Montague et al., 1996; reviewed in Schultz et al., 
1997). Its plausibility was reviewed in human fMRI studies (D'Ardenne et al., 2008) and multiple 
electrophysiological experiments and species (Day et al., 2007; Eshel et al., 2015; Fiorillo et al., 
2003; Roesch et al., 2007). Moreover, it has been proposed that the RPE signal, i.e. 
dopaminergic activity acting as a learning signal, plays a vital role in reinforcement learning. 





types of learning such as Pavlovian, contextual or operant learning (reviewed in Cox and Witten, 
2019; Hamid et al., 2016; Saunders et al., 2018; Tsai et al., 2009).  
The NAc as key player of the reward circuit consists in large part of GABAergic medium spiny 
neurons (MSN) (Kemp and Powell, 1971; Preston et al., 1980; Somogyi et al., 1981). Its 
functional outcome is modulated by GABAergic and cholinergic interneurons and mainly leads 
to the acknowledgment of reward and the resulting quest for its fulfillment. MSN in the 
striatum either express D1 dopamine receptors (D1R) or D2 dopamine receptors (D2R), which 
inhibit (direct pathway) or increase (indirect pathway) the basal ganglia output, respectively. 
By modulating the firing rate of the basal ganglia output nuclei, they regulate and encode action 
(reviewed in Cox and Witten, 2019). During value-based decision-making, D1R MSN respond 
with greater activity to reward presentation, whereas D2R MSN react to unexpected reward 
(Nonomura et al., 2018). Similar effects can be found in Pavlovian learning with a positively 
correlated increase to reward-predicting cues of D1R MSN and negatively correlated response 
of D2R MSN (Shin et al., 2018).  
The actual processing of reward, i.e. primary and secondary rewards, could be demonstrated 
by PET and fMRI studies which showed increased activation of striatal areas (Blood and Zatorre, 
2001; Delgado et al., 2000; Elliott et al., 2000; Knutson et al., 2000; Menon and Levitin, 2005). 
In line with the aforementioned description of striatal projections, fMRI studies revealed 
activation in the OFC during primary reward anticipation as well as reward outcome (O'Doherty 
et al., 2001; Rolls et al., 2003). Furthermore, the tight connection to the midbrain, or better its 
involvement in reward processing, has also been examined. FMRI studies revealed enhanced 
activation of the midbrain during the anticipation of reward and also during the visual 
presentation of reward-predicting cues (D'Ardenne et al., 2008; O'Doherty et al., 2002; 
Wittmann et al., 2005).   
Taken together, the ventral striatum and its associated mesolimbic and mesocortical networks 
have repeatedly been defined as key players in reward processing which also influences 
decision-making. Due to the reliable effects, they provide a great foundation to examine reward 
processing with fMRI.  
1.2.1.2    Alterations in reward processing of bipolar and schizophrenia patients 
In chapters 1.1.1.3 and 1.1.2.3, abnormalities in the dopaminergic pathways of bipolar disorder 
and schizophrenia patients were described which might affect their dopaminergic modulated 
reward circuit. Therefore, the next paragraphs will summarize the experimental evidence for 
alterations in the reward processing of the two disorders.  
As mentioned in previous chapters, patients with bipolar disorder seem to have abnormally 





reported abnormal activation in the ventral striatum and PFC during reward-related paradigms 
(Abler et al., 2008; Dutra et al., 2015; Yip et al., 2015). A study by Caseras et al. (2013) 
demonstrated atypically increased activation in the ventral striatum of bipolar disorder II 
patients during reward anticipation compared to healthy controls. In concordance, Mason et 
al. (2014) detected a significant increase in the left ventral striatum for high-probability rewards 
(relative to low) in bipolar patients but not healthy controls. They proposed that other than in 
healthy controls, bipolar patients’ ventral striatum might have a stronger effect on suboptimal 
decision making, so that lower-order desires are preferred over long-term goal rewards. This 
would also imply an alteration of ventromedial PFC activity as it is responsible for the 
integration and weighting of signals from the dorsolateral PFC (long-term goal representation) 
and ventral striatum (lower order-preferences). This is in line with a study of Nusslock et al. 
(2012) who described elevated striatal and OFC activity during reward anticipation, suggesting 
activation in the ventral striatum and OFC as a functional marker for bipolar disorder while at 
the same time explaining a predisposition to (hypo)mania. In contrast, Trost et al. (2014) 
reported reduced activation in the ventral striatum in bipolar patients compared to healthy 
controls. However, they argued that compromised top-down regulation of prefrontal areas on 
the ventral striatum led to this effect. This interpretation could also be supported by their 
additional findings describing a dysfunctional connectivity pattern between anteroventral 
prefrontal cortex (avPFC) and ventral striatum. Similarly, studies examining reward anticipation 
and anticipation-related arousal have identified aberrant activation in the left ventrolateral PFC 
in bipolar patients (Chase et al., 2013; Dolcos et al., 2004). Furthermore, a PET study from 
Anand et al. (2011) showed that unmedicated bipolar patients seem to have a dysfunction in 
dopamine transmission due to significantly less dopamine transporter (DAT) availability. They 
proposed that in consequence, more dopamine might remain in the synaptic cleft leading to 
the state of hyperdopaminergia. In addition, a translational study revealed that mice with 
chronic or acute DAT depletion demonstrated impaired decision-making in a rodent version of 
the Iowa Gambling Task (IGT) (van Enkhuizen et al., 2014). They compared this behavior to 
bipolar disorder patients also performing the IGT and found the same deficient decision-making 
profile. 
Taken together, the specific effects of abnormal reward processing differ between hyper- and 
hypoactivation in relevant brain areas of bipolar patients. Characteristic activations could also 
be linked to differential affective phases, i.e. manic or depressed, medication status, i.e. 
medication-naïve or low- or high dosage medication, or heterogeneous clinical appearance etc. 
that have been examined in the various studies. However, it can be concluded that abnormal 
activation in the ventral striatum and frontal brain areas indicate a dysfunction of dopaminergic 





The reward processing system has also been reported to be disturbed in schizophrenia patients. 
Again, the ventral striatum appears to be a key area associated with aberrant reward 
modulation (reviewed in Chase et al., 2018). In various experiments involving reward-related 
tasks, decreased activation in the ventral striatum of schizophrenia patients compared to 
healthy controls was reported (Esslinger et al., 2012; Juckel et al., 2006b; Schlagenhauf et al., 
2009). In contrast, more recent studies presented increased activation in the ventral striatum 
during paradigms associated with reward processing (Morris et al., 2012; Richter et al., 2015; 
Tikasz et al., 2019). The study by Richter et al. applied the desire-reason-dilemma paradigm, 
which was also used in this thesis, and detected significantly enhanced brain activation in the 
ventral striatum in response to conditioned reward stimuli. Furthermore, they showed a 
disrupted top-down influence of the PFC on the ventral striatum and VTA during reward stimuli 
presentation. The influence of dopamine on the ventral striatum particularly during reward 
processing was also confirmed by a study of Wulff et al. who examined the fMRI response in a 
monetary incentive delay task in antipsychotic-naïve schizophrenia patients (Wulff et al., 2019). 
They found decreased activation in the caudate nucleus of schizophrenia patients compared to 
healthy individuals. Their follow-up measurement after six weeks of amisulpride exposed that 
patients responding to the antipsychotic treatment had an enhanced BOLD response in the 
nucleus caudate. These findings are in line with earlier studies showing that patients treated 
with atypical antipsychotics had comparable functional responses to reward-indicating cues as 
healthy controls, but patients treated with typical antipsychotics had reduced activation in the 
left ventral striatum (Juckel et al., 2006a; Schlagenhauf et al., 2008). In sum, it can be stated 
that the aforementioned deficits in dopaminergic modulation most likely influence the 
reported alterations in brain activation during reward processing of schizophrenia patients. 
1.2.2    Attentional processing 
1.2.2.1    Attention: oddball & incongruence effects 
Attention is a cognitive process that entails various subtopics and wide-spread hypotheses. In 
general, attention is defined as a condition of selectively processing concurrent stimuli (Bear et 
al. 2007, p.644). In this chapter the neural correlates of goal-directed behavior and stimulus-
driven attention will be further illuminated. With respect to the paradigm used in this study, it 
will be focused on the incongruence and oddball effect.  
The most famous incongruence task was developed by Stroop in 1935 (Stroop, 1935). He 
published the results of a study introducing a task which aimed at creating inference in the 
participants. In this task, the individuals were asked to call the print color of words ignoring the 
colors named by the words, e.g. the word “green” was printed in red and therefore had to be 
called “red”. Back then, Stroop demonstrated significantly enhanced reaction times in the 





to name the color of a color patch or neutral stimuli, respectively. He concluded that the 
processing of the irrelevant task dimension led to an interference with the relevant task. Since 
then, the reduction of the response speed during incongruent compared to congruent stimuli 
has been replicated multiple times and has ever since been named “Stroop effect”. It could also 
be detected in nonhuman primates confirming the robustness of the Stroop interference even 
across species (Allritz et al., 2016; Beran et al., 2007; Washburn, 1994; reviewed in Washburn, 
2016). Over the years various tasks and paradigms have been developed, such as Flanker, 
Simon, Go/No-Go or Stop-Signal test (Eriksen and Eriksen, 1974; Logan and Cowan, 1984; 
Simon and Small, 1969). Most of them involve a task-relevant and task-irrelevant dimension 
with the latter conflicting with the appropriate response reaction. They all have in common 
that the participants fail, on the one hand, to concentrate on the relevant stimulus and, on the 
other hand, to control the suppression of the information provided by irrelevant stimuli. One 
possible interpretation for the Stroop phenomenon has been developed by Cohen et al. (1990) 
who established a model which describes a two-route neural network with three layers. One 
route is responsible for the color identification of the stimulus and the other for its meaning. 
The three layers reflect the stimulus representation, response activation and interaction 
between the two routes during processing. Botvinick et al. (2001) added a conflict-monitoring 
model unit and described control as dynamic processes that are elicited by the level of conflict. 
In the paradigm used here, the incongruence condition comprises a color-shape conflict, where 
attention to the irrelevant task dimension interferes with the response to be given regarding 
the relevant task dimension resulting in prolonged reaction times (Gruber et al., 2009).  
Another specific cognitive effect which will be part of this study is induced by the oddball 
stimulus. In tasks involving an oddball stimulus, participants are instructed to distinguish rare 
target stimuli (oddballs) from a series of frequent standard stimuli. Oddball effects were 
reported for the first time in event-related potential (ERP) measures, when the response of 
participants to the oddball stimuli was recorded via electroencephalogram (Squires et al., 
1975). ERPs which were elicited specifically after the presentation of the oddball stimulus, were 
named P300 as they usually occur 300ms after the stimulus presentation (reviewed in Picton, 
1992). An ERP comparable to the P300 component could also be detected in nonhuman 
primates (Arthur and Starr, 1984; Glover et al., 1986). Additionally, auditory-evoked potential 
P300-responses following the presentation of oddball stimuli have recently been described in 
rodents (Ahnaou et al., 2018). These animal studies underline the reliability of the oddball 
effect across species.  
The combined oddball-incongruence paradigm used in this study forms a combination of both 
effects. It has previously been hypothesized that response conflicts and reactions to relevant 
stimuli might induce similar cognitive processes (Gruber et al., 2010; Gruber et al., 2009). Every 





attention is shifted towards the stimulus (reviewed in Corbetta and Shulman, 2002). In general, 
humans constantly keep a frail balance between focusing on task-relevant information and at 
the same time processing potentially threatening or rewarding but task-irrelevant background 
information. These salient or novel stimuli need to be quickly prioritized in case of an 
emergency and will thereby disrupt the ongoing behavior. Both, top-down and bottom-up, 
processes are involved in the regulation of this attention equilibrium. On the one hand, 
cognitive features such as knowledge, experience, current goals etc. modulate visual attention. 
On the other hand, sensory stimulation can interfere with it and thereby steer the attention in 
certain directions. A novel or unexpected stimulus can evoke a rapid switch of attention to a 
new target dimension (reviewed in Corbetta et al., 2008).  
Taken together, the incongruence and oddball effects offer a great possibility to investigate 
potential differences in specific processes of attention in bipolar and schizophrenia patients.  
1.2.2.2    Brain regions associated with the incongruence and oddball effect 
This paragraph will describe the underlying brain structures associated with the incongruence 
and oddball effects. Regions mostly reported to be involved in the processing of incongruence 
and oddball tasks are part of the frontoparietal network.  
A recent large-scale meta-analysis studying the functional neural network of response 
inhibition processes, found great overlapping in activation of the frontoparietal and ventral 
attentional systems (reviewed in Zhang et al., 2017). Other meta-analyses support these 
findings and additionally underline the involvement of the anterior cingulate cortex (reviewed 
in Cieslik et al., 2015; reviewed in Nee et al., 2007). Frontal brain regions reported to be 
associated with response inhibition have been the right inferior frontal gyrus, anterior insula 
and dorsolateral PFC (Durston et al., 2003). In addition, parietal brain regions such as the 
intraparietal cortex and superior parietal cortex were described to be involved in attentional 
conflicts. Another study demonstrated significant activations in the anterior cingulate and left 
PFC in three different conflict tasks (Fan et al., 2003). However, they also found varying 
activation localizations in the different tasks. A study by Zysset et al. used the Stroop paradigm 
to examine interference and found the lateral PFC, intraparietal cortex and occipitotemporal 
gyrus to be activated in the incongruent versus neutral condition (Zysset et al., 2001). They 
argued that activation in the anterior cingulate cortex which is often reported in conjunction 
with incongruence effects does not reflect interference but rather a degree of conflict. All in 
all, frontoparietal regions as well as the anterior cingulate cortex have reliably been shown to 
activate during interference tasks.  
Nonhuman primate studies investigating the underlying brain regions involved in the 





(Schall et al., 1995; Thompson et al., 1996). Furthermore, single-cell recordings revealed that 
bottom-up processing of salient stimuli was located in the lateral intraparietal area (Arcizet et 
al., 2011; Constantinidis and Steinmetz, 2005). This is in line with human fMRI experiments 
which repeatedly demonstrated activation of the frontoparietal network during oddball tasks. 
They mostly reported activation patterns in the PFC, temporoparietal junction and superior 
parietal cortex (Bledowski et al., 2004; Huettel et al., 2002; Milham et al., 2003). A study by 
Bledowski et al. (2004) emphasized the common influence of the temporoparietal junction and 
right PFC on target and distractor processing. They concluded that subsystems are recruited 
for the modulation of specific tasks associated with memory and attention. Amongst others, 
Kiehl et al. and Braver et al. both discussed the engagement of the anterior cingulate cortex in 
target detection (Braver et al., 2001; Kiehl et al., 2001). A recent combined ERP-fMRI oddball 
study showed activations in the inferior frontal gyrus, anterior insula, extrastriate occipital and 
supplementary motor area as well as close to the anterior intraparietal cortex (Ragazzoni et al., 
2019). Similar results have been found in earlier ERP-fMRI studies by Rusiniak et al. (2013) and 
Strobel et al. (2008) who examined a modified oddball paradigm. 
A review from almost twenty years ago used over 250 studies to investigate the functional 
neuroanatomy of various cognitive tasks, inter alia attention. They found consistent activations 
in parietal and prefrontal regions during various tasks associated with cognitive control 
(reviewed in Cabeza and Nyberg, 2000). One specific frontal region that has been reported to 
be involved in cognitive control processes in different meta-analyses is the inferior frontal 
junction (reviewed in Derrfuss et al., 2005; reviewed in Neumann et al., 2005). These more 
general results overlap with brain areas that were reported independently during the 
incongruence and oddball tasks and therefore strongly indicate a shared underlying attention 
processing network.  
The general model of cognitive control involves bottom-up attention processes that are 
supposed to derive from the visual cortex and project via the ventral or dorsal pathway to the 
PFC (reviewed in Corbetta and Shulman, 2002). In contrast to the automatically initiated 
stimulus-driven processes, top-down attention is voluntary, directing one’s attention to a 






FIGURE 1 Hypothetical model of key projections of the visual attention circuit from Corbetta and Shulman 
(reviewed in Corbetta and Shulman, 2002). In the bottom-up attention processing, visual areas transmit 
visual information to the frontal eye field (FEF) and intraparietal cortex (IP) as well as via the 
temporoparietal junction (TPJ) to the ventral  frontal cortex (VFC). The FEF is involved in the top-down 
integration of experiences, motivation etc. into the processing of visual stimuli, and projects to the IP 
and visual cortex. Illustration created in BioRender.com. 
 
1.2.2.3    Implications of bipolar disorder and schizophrenia on the incongruence and oddball 
effect 
In general, it is well known that patients with bipolar disorder or schizophrenia suffer from 
cognitive impairment in many domains of attentional processes (Collier et al., 2014; Mohn and 
Torgalsboen, 2018; reviewed in Robinson et al., 2006; reviewed in Torres et al., 2007; Wang et 
al., 2005). Executive control has been extensively researched in both disorders and suggests 
the idea of gradual dysfunctions. Schizophrenia patients seem to have the greatest deficits, 
whereas bipolar patients usually show intermediate malfunction (Melcher et al., 2014). In the 
following, fMRI studies investigating brain regions associated with disturbances of bipolar and 
schizophrenia patients in cognitive control processes, in particular regarding the incongruence 
and oddball effect, will be summarized.   
Overall, fMRI studies examining inhibitory control effects in bipolar disorder consistently report 
hypoactivations compared to healthy controls (Altshuler et al., 2005; Blumberg et al., 2003; 
Kaladjian et al., 2009; Kronhaus et al., 2006; Penfold et al., 2015; Strakowski et al., 2008; 
Strakowski et al., 2005; Townsend et al., 2012). These reduced activations were found 
independently of their mood states, i.e. manic, depressed or euthymic, and comprised frontal, 
temporal and parietal regions, as well as subcortical areas such as the basal ganglia. 
Hypoactivation in particular in the right inferior frontal gyrus might constitute a trait marker for 





analysis by Hajek et al. reported thus hyperactivations specific for euthymic bipolar patients 
compared to healthy controls in cortical brain areas such as the right middle frontal and left 
superior temporal gyrus (reviewed in Hajek et al., 2013). A more recent meta-analysis found 
hyperactivation or deficient deactivation in the left precentral, left superior frontal and right 
superior temporal gyri independent of the patients’ mood state (reviewed in Alustiza et al., 
2017). In that respect, it is important to note that the meta-analysis included a broad spectrum 
of cognitive control tasks, including visual emotion regulation tasks etc.  
A meta-analysis comparing schizophrenia patients and healthy controls outlined 
hypoactivations in frontal, cingulate and parietal brain regions as well as the left thalamus 
linked to cognitive control processes (reviewed in Minzenberg et al., 2009). A more recent 
meta-analysis identified reduced activations in mainly the same brain structures (reviewed in 
Alustiza et al., 2017). Overall, deficits in cognitive control of schizophrenia patients seem to 
reflect in hypoactivations mainly in frontal and cingulate brain areas (Lesh et al., 2013; Wagner 
et al., 2013). Additionally, the two meta-analyses also reported enhanced activations of 
schizophrenia patients compared to healthy controls (Alustiza et al., 2017; Minzenberg et al., 
2009). However, the hyperactivated brain regions varied strongly between both studies 
including the rostral pole of the left PFC, left dorsal and ventral premotor areas, dorsal anterior 
cingulate cortex and subcortical regions (Minzenberg et al., 2009) compared to the right middle 
occipital gyrus and bilateral precentral gyrus (Alustiza et al., 2017). These results differ from the 
findings of a study by Wolter et al. who described hyperactivations in the intraparietal cortex, 
left inferior parietal lobule, right middle temporal gyrus (MTG) and left intra-occipital lobe as 
well as the VTA. They argued that increased activation in the reorienting network and 
dopaminergic midbrain underline the aberrant salience theory of schizophrenia (Kapur, 2003). 
It can be concluded that the current literature does not provide a completely homogeneous 
and clear picture regarding interference dysfunctions of bipolar and schizophrenia patients. 
This might result from strongly varying tasks (e.g. Stroop, Go/ No-Go, Flanker, etc.) and task 
presentations (e.g. auditory, visual, multisensory, etc.) as well as in many cases very small 
sample sizes.  
Regarding the oddball effect, Morey et al. revealed that schizophrenia patients showed less 
activation in frontostriatal areas during a visual oddball task in comparison to healthy controls 
(Morey et al., 2005). Additionally, another study reported hypoactivations in intraparietal 
areas, the dorsal frontal cortex as well as subcortical regions such as thalamus and basal ganglia 
during novel stimulus processing (Laurens et al., 2005). Contrary, an oddball paradigm by Gur 
et al. (2007) discovered hyperactivations in occipital-parietal and frontal areas. They only found 
reduced activation in the visual cortex and right inferior parietal lobule. Another auditory 
oddball paradigm exhibited hyperactivation in the right temporal cortex, left superior frontal 





schizophrenia patients might disturb speech processing leading to a disruptive functional 
network (Ngan et al., 2003). In addition, Wolter et al. (2016) detected significantly enhanced 
activation of schizophrenia patients in the bilateral intraparietal cortex and VTA. As mentioned 
before, they associated their results to the aberrant salient network of schizophrenia patients. 
Taken together, brain activation abnormalities in schizophrenia patients’ novelty detection 
processing differed between the presented studies. Again, the task designs might not be well 
comparable, and the samples were very heterogeneous. This explanation is supported by a 
study from Collier et al. who found significant differences in the brain activation of 
schizophrenia patients in the comparison between an auditory and visual oddball paradigm 
(Collier et al., 2014). 
A recent study used a passive auditory oddball paradigm to compare mismatch negativity 
(MMN) of schizophrenia and bipolar patients with EEG and structural MRI. Both patient groups 
demonstrated significantly reduced MMN amplitudes in comparison to healthy individuals. In 
addition, they found an association between MMN decrease and cortical thinning in frontal and 
temporal regions of the patients’ brains (Kim et al., 2019). A combined fMRI-diffusion tensor 
imaging (DTI) study looked at differences between bipolar and schizophrenia patients during 
an auditory oddball task. They discovered a similar malfunction of the dorsolateral PFC and 
thalamus in the two patient groups compared to healthy controls. Furthermore, bipolar and 
schizophrenia patients could be discriminated on the basis of activation differences in the 
parahippocampal gyrus and visual cortex (Sui et al., 2011). No further studies examining the 
oddball effect in bipolar patients with fMRI could be found. Therefore, it is important to provide 
new insights regarding the manifestation of the oddball effect in bipolar disorder 
1.3   Functional magnetic response imaging 
In 1946 the basics of magnetic resonance imaging, i.e. nuclear magnetic resonance (NMR) were 
developed and reported by Bloch (1946) and Purcell et al. (1946). Further advancements by 
Lauterbur (1973) and Mansfield (1977) led eventually to the clinical application of MRI as we 
know and use it today. Its broad field of application makes MRI a unique and very popular 
technique. The selection of measuring parameters, i.e. diffusion-, proton density- and 
relaxation time- weighted images permits the visualization of tissue differences, or contrasts. 
Every (hydrogen) proton has an intrinsic spin around its own axis caused by thermal energy. 
When the nuclei are placed in an external magnetic field the spins start precessing around the 
axis of the field direction. They can either precess parallel or antiparallel to the magnetic field. 
The parallel formation needs less energy and is therefore called “low energy state”, whereas 
the antiparallel direction is named “high energy state”. The longitudinal magnetization is 
defined by the net magnetization which is parallel to the magnetic field. During the excitation, 
longitudinal magnetization is converted to transverse magnetization. In the process energy at 





energy state of most nuclei. As soon as the energy is removed from the nuclei, they return to 
their original low energy state and thereby release the previously absorbed energy. The emitted 
energy can be detected by the scanner hardware and leads to the recording of MR signals 
(reception). Changes of these MR signals are called relaxation. There are two types of 
relaxation: T1 and T2*, describing the recovery of the longitudinal magnetization or decay of 
the transverse magnetization, respectively (Huettel et al., 2009, pp.57-67).  
Less than 20 years later, it became apparent that cerebral blood flow can work as the body’s 
own contrast agent, i.e. blood oxygen level dependency (BOLD). Oxygen is transported via 
hemoglobin in the blood. The so-called oxygenated hemoglobin contains an iron atom, which 
binds the oxygen and thus has similar magnetic features as the surrounding brain tissue. 
Desoxygenated hemoglobin, on the other hand, is paramagnetic. During neural activity local 
blood flow overcompensates the oxygen consumption with an increase of oxygenated 
hemoglobin leading to a local increase in T2* relaxation, i.e. an increase of MR signal in T2*-
weighted images (Fox and Raichle, 1986; Ogawa et al., 1990). The MR signal peaks four seconds 
after neuronal activity and is followed by a short phase of deactivation afterwards. Shortly after, 
an equilibrium between oxygenated and desoxygenated hemoglobin will evolve. This is called 
the hemodynamic response function (HRF). Under the assumption that neural response and 
BOLD signals exhibit linear time variant properties, a general linear model can be applied to 
analyze the activation of each voxel at different time points (Friston et al., 1994). An indicator 
function with the onsets of the events is convoluted with a canonical HRF resulting in a design 
matrix, i.e. a predicted HRF for each experimental condition. In the following, statistical tests 
can be applied to identify significant activation differences between voxels in the respective 
experimental conditions. 
1.4   Aims of the present thesis 
As presented in previous chapters, a lot of research has been conducted to better understand 
the underlying pathophysiologies of bipolar disorder and schizophrenia. Even though many 
characteristics and properties regarding behavioral, structural and functional abnormalities 
have been found and described in the respective disorders over the years, there are still 
remaining pieces to the puzzle. This doctoral thesis aimed to tackle some of these open 
questions and in particular investigate the underlying neural correlates of attentional processes 
and reward circuits in bipolar disorder and schizophrenia.  
The thesis was divided in two studies throughout the methods, results and discussion section, 
as they focused on two different research questions. The first study concentrated on diagnosis-
specific brain activation differences in attention processing, whereas the second study was 





response prediction. For a better understanding, it is recommended to read the corresponding 
subchapters of each study separately.  
Study A was conducted to explore the neural correlates of attentional processes in bipolar 
disorder and schizophrenia. As reported in previous chapters, cognitive dysfunctions in 
particular during cognitive control processes are crucial symptoms of both psychiatric 
disorders. A better understanding of alterations in their functional responses during inhibitory 
control and novelty processing might improve the overall comprehension of pathophysiological 
processes in bipolar disorder and schizophrenia. On the basis of a previous study that reported 
hyperactivations of schizophrenia patients in the intraparietal cortex during the same 
combined oddball-incongruence paradigm, it was tried to replicate those findings in a larger 
schizophrenia sample and additionally investigate potential equally disturbed effects in bipolar 
disorder. The aim was to compare cortical activations of the individual diagnoses and healthy 
controls using fMRI. It was hypothesized that previously found frontoparietal activations of 
healthy individuals as well as hyperactivations in the intraparietal cortex of schizophrenia 
patients might constitute differences that provide deeper insights into the pathophysiology of 
the two disorders. Furthermore, performances of the patients and healthy controls were 
investigated. It was hypothesized that the attentional capacity might be impaired in the 
patients’ groups and that schizophrenia patients might have greater difficulties than bipolar 
disorder patients.  
Study B aimed to further investigate whether differential treatment response might also 
identify different pathomechanisms. The current psychopharmacological treatment of 
schizophrenia and bipolar disorder is mostly decided on the basis of clinical appearance and 
experience of the psychiatrist but does not include neurobiological features or standardized 
measures. This is owed to the fact that neuroimaging biomarkers found so far in bipolar 
disorder or schizophrenia, primarily divided between diagnosis groups. Clinicians, however, 
treat individuals and not groups of patients. To avoid mistakes and give patients the best 
possible treatment a priori, it would thus be of great interest to identify independent markers 
that could predict treatment response. SVM methods offer a solution to classify patients on an 
individual level and additionally are sensitive to small effects in brain activation. Furthermore, 
the discovery of biomarkers would potentially open up the development of new therapeutics 
that might target individual symptoms of the patients more specifically. Taking the advantages 
of treatment prediction into account, study B concentrated on detecting functional differences 
in the brain activation of responders and non-responders of bipolar and schizophrenia patients 
within their respective treatment groups, i.e. atypical or typical antipsychotics or aripiprazole. 
The main goal was to identify specific differences of the individual treatment arms, i.e. 
subgroup-specific hyperactivations or deactivations during the reward-related desire-reason-





schizophrenia patients so far. The underlying alterations of the dopaminergic transmission 
system are the target of all antipsychotic medication. Therefore, a reward-related paradigm 
offers a great approach to look for prognostic biomarkers for treatment response. It was 
hypothesized that regions which might present activation differences would possibly be 
associated with reward-associated brain structures, such as the ventral striatum or VTA. On the 
basis of previous studies examining reward processing of bipolar and schizophrenia patients, it 
was thought that the heterogeneity within both disorders might affect activation in the 
mesolimbic or prefrontal brain areas so that subgroups demonstrate differential response to 
antipsychotic treatment. Parameter estimates of brain regions that showed reward-related 
activation differences between responders and non-responders were applied to SVM 
algorithms in the following to explore possible predictors for treatment success of the 
individual neuroleptic treatment. Overall, the aim was to identify (de)activated brain regions 
that might potentially be able to predict the individual treatment response to specific 
subgroups of antipsychotic medication of the patients. This is the first time SVM algorithms are 
applied to neuroimaging data related to reward processing to predict treatment response of 
specific neuroleptic subclasses. 
Taken together, results of the current literature on cognitive control and reward processes of 
schizophrenia and bipolar disorder urge for a better comprehension of both psychiatric 
diseases. Understanding the attentional and reward-related pathways and networks could help 
to develop multimodal biomarkers that might ultimately benefit treating patients more 






2.1   Subjects 
This thesis comprises two different studies which differ in the implemented paradigms and 
sample composition. Patients of both studies and healthy controls were enrolled by Dr. Sarah 
Trost and Aleksandra Petrovic from the Department of Psychiatry and Psychotherapy, 
University Medical Center Göttingen. After receiving complete information about the study and 
being able to ask questions, subjects had to sign a written informed consent. The studies were 
approved by the Göttingen Ethics Committee and underlay the latest version of the Declaration 
of Helsinki. As compensation for their participation, all probands received an expense 
allowance. To avoid undesirable effects of uncontrollable factors, the following exclusion 
criteria were defined: lifetime diagnoses of substance dependence, substance abuse during the 
last month, cannabis abuse within the last two weeks, mental retardation, severe somatic 
diseases, claustrophobia, achondroplasia and neurological diseases. 
2.1.1    Study A: Executive network dysfunction of bipolar and schizophrenia patients 
In study A, 90 subjects were recruited for a combined oddball-incongruence fMRI paradigm. 
Twenty of the participating patients were diagnosed with bipolar disorder and thirty patients 
with schizophrenia according to ICD-10 classification standards. In addition, forty healthy 
controls were recruited and matched with the patients’ demographics. Gender, school 
education, handedness and age of the participants as well as the scores from 
psychopathological scales such as Montgomery-Asberg Depression Scale (MADRS), Young 
Mania Rating Scale (YMRS), Positive and Negative Symptom Scale (PANSS) and Clinical Global 





TABLE 1 Overview of the demographic and clinical data of bipolar and schizophrenia patients as well as 
healthy controls included in the combined oddball-incongruence study. 
  bipolar disorder schizophrenia healthy controls 
  N Mean (SD) N Mean (SD) N Mean (SD) 
Demographic data        
 total 20 - 30 - 40 - 
gender female 12 - 4 - 15 - 
 male 8 - 26 - 25 - 
school education < 9 years 2 - 3 - 1 - 
 10 years 5 - 6 - 3 - 
 > 13 years 13 - 21 - 36 - 
handedness right 20 - 26 - 37 - 
 left 0 - 4 - 3 - 
age  years - 39.30 (12.54) - 29.83 (7.79) - 33.10 (9.10) 
Clinical data        
 age of onset - 26.25 (10.39) - 23.29 (5.08) - - 
 MADRS - 8.45 (7.56) - 9.37 (7.03) - - 
 CGI - 3.55 (1.23) - 3.9 (1.12) - - 
 YMRS - 3.85 (4.55) - - - - 
 PANSS - - - 49.73 (12.15) - - 
Medication        
Atypical antipsychotics 14 - 27 - - - 
Typical antipsychotics 7 - 4 - - - 
Antidepressants 11 - 11 - - - 
Mood stabilizers 4 - 0 - - - 
Anticonvulsants 15 - 0 - - - 
Abbreviations: SD= standard deviation, MADRS= Montgomery-Asberg Depression Scale, CGI: Clinical 
Global Impression Scale, YMRS= Young Mania Rating Scale, PANSS= Positive and Negative Symptom 
Scale 
 
2.1.2    Study B: Treatment response prediction in bipolar and schizophrenia patients 
In study B, 38 patients were recruited from the Department of Psychiatry and Psychotherapy, 
University Medical Center Göttingen. Twenty-eight of these patients met the criteria of 
schizophrenia and ten patients of bipolar disorder according to ICD-10 classification standards. 
Table 2 contains the demographic and clinical data of the patients.  
The patients’ medical records were retrospectively examined for successful and failed 
psychopharmacological treatment. Based on this information, patients were divided into 
groups of responders and non-responders to either atypical, typical antipsychotics or 
aripiprazole. The classification of those patients was independently of their medication at the 





TABLE 2 Overview of demographic and clinical data of the patients and healthy individuals from the treatment response prediction study. 
  Atypical antipsychotic Typical antipsychotic Aripiprazole 
  responders non-responders responders non-responders responders non-responders 
  
N mean N mean N mean N mean N mean N mean 
total  15 - 7 - 2 - 4 - 7 - 3 - 
gender female 0 - 4 - 0 - 1 - 5 - 1 - 
 male 15 - 3 - 2 - 3 - 2 - 2 - 
school education < 9 years 2 - 1 - 1 - 0 - 0 - 0 - 
 10 years 4 - 2 - 1 - 0 - 4 - 0 - 
 > 13 years 9 - 4 - 0 - 4 - 3 - 3 - 
handedness right 12 - 6 - 2 - 4 - 6 - 2 - 
 left 3 - 1 - 0 - 0 - 1 - 1 - 























































 YMRS - 12 - 4.33 - - - 2 - - - - 
 PANSS - 47.38 (SD: 
14.89) 
- 43.00 (SD: 
7.35) 
- 38.5 - 54.67 (SD: 
16.44) 
- - - - 
Medication at time 
of investigation Atypical antipsychotics 13/15 - 6/7 - 2/2 - 3/4 - 5/7 - 3/3 - 
 Typical antipsychotics 0/15 - 1/7 - 2/2 - 0/4 - 2/7 - 1/3 - 
 Aripiprazole 3/15 - 1/7 - 0/2 - 1/4 - 4/7 - 1/3 - 
 Antidepressants 5/15 - 3/7 - 1/2 - 2/4 - 2/7 - 0/3 - 
 Mood stabilizer 2/15 - 1/7 - 0/2 - 1/4 - 1/7 - 0/3 - 
 Anticonvulsants 2/15 - 1/7 - 0/2 - 1/4 - 3/7 - 0/3 - 
 Benzodiazepines 1/15 - 0/7 - 0/2 - 0/4 - 0/7 - 0/3 - 
Abbreviations: SD= standard deviation, MADRS= Montgomery-Asberg Depression Scale, CGI: Clinical Global Impression Scale, YMRS= Young Mania Rating Scale, 





2.2   Experimental tasks 
2.2.1    Study A: Combined oddball-incongruence paradigm 
In study A subjects underwent fMRI while performing a combined oddball-incongruence 
paradigm (Gruber et al., 2009). At the beginning, all subjects were verbally instructed outside 
the scanner. They were asked to classify geometric objects according to either color or shape 
as quickly as possible. In a pseudo-random trial-by-trial manner, task cues indicated whether 
the color or shape should be classified.  
The task cue was presented for 500ms, followed by a short 250ms cue-stimulus interval and a 
750ms presentation of the relevant stimulus. Within 1000ms, subjects had to respond to the 
stimulus, i.e. 750ms stimulus display + 250ms stimulus-cue interval. In the shape condition, 
subjects had to press the left button with their index finger for the slim object and the right 
button with their middle finger for the broad object. In the color condition, participants had to 
push the left button for the red object and the right button for the blue object. All participants 
were instructed to respond with their right hand. 
Since all objects consisted of two dimensions, subjects had to differ between relevant and 
irrelevant dimensions during the task. They had to respond to the relevant dimension, i.e. the 
condition indicated by the task cue, and ignore the irrelevant dimension. These two dimensions 
lead to four conditions: color congruent, color incongruent, shape congruent and shape 
incongruent. In the congruent conditions, response to the stimulus matched the same button, 
i.e. the red color and slim object or the blue color and broad object. During the incongruent 
conditions, the responses to the stimulus were mapped on two different buttons, i.e. the red 
color and broad object or the blue color and slim object. In addition, a fifth condition, the so-
called “oddball” was integrated. It was rarely displayed and constituted of a white stimulus 
(either slim or broad), which should always be allocated regarding its shape. For a visual 






FIGURE 2 Graphical presentation of the combined oddball-incongruence paradigm. Each trial contained 
a relevant and an irrelevant dimension. During the color condition, the color of the object (red or blue) 
represented the relevant and its shape the irrelevant dimension. During the shape condition, the shape 
of the object (slim or broad) depicted the relevant dimension, whereas the color was irrelevant. During 
the oddball trials participants had to ignore the rare color of the object, i.e. white, and respond only to 
its shape. Responses “red” and “slim” were mapped on the left button and responses “blue” and 
“broad” on the right button. Illustration created with Inkscape 0.92.3. 
 
2.2.2    Study B: Desire-reason-dilemma paradigm 
In study B the patients underwent the desire-reason-dilemma (DRD) paradigm (Diekhof and 
Gruber, 2010). At first, the patients were verbally instructed and performed a conditioning task. 
The stimuli were presented on a screen outside the MRI scanner. In this task, squares in eight 
different colors were alternately presented on a neutral grey background on the monitor. 
Subjects were instructed to identify the rewarded and punished colors by trial-and-error via 
free button press of their right hand. The left button was allocated to collecting a certain color, 
whereas the right button was allocated to rejecting the color. The software was programmed 
to display the stimulus on the screen until one of the buttons was pressed. Following the 
response, participants immediately obtained feedback whether the selected color was 
associated with a reward (bonus of +10 points, i.e. red and green) or a punishment (-10 points; 
purple and brown) or if the stimulus color was neutral (0 points; yellow, pink, turquoise, blue). 
Green and red remained the two rewarded colors throughout the rest of the experiment. 
In the second part, patients underwent the actual DRD paradigm. This task was trained first 
outside the scanner until the patients collected at least 500 points, but not more than three 
times. The task consisted of two different round types- the bonus (or ‘desire context’) and the 
target (or ‘reason context’) round alternating after two blocks. In both rounds, subjects had to 
pursue a superordinate long-term goal, i.e. correctly responding to stimuli to collect 50 points. 
Each block consisted of four or eight trials. At the beginning of the block, two target colors were 





round, indicated as ‘T’ (in the German version the letter ‘Z’ was presented for the German word 
of target, i.e. ‘Ziel’), patients had to collect all target colors and reject all non-target and the 
bonus colors to receive 50 points at the end of the block. During the bonus round, indicated as 
‘B’, patients were asked to collect target colors and the previously learned bonuses, i.e. 
rewarded colors. Each collected bonus color added 10 points to the total outcome of each 
block. Rejecting a bonus cue in the desire condition did not terminate the block. It follows from 
this design that the subjects had to actively suppress the impulse to accept the bonus colors 
during the reason context in order to achieve the superordinate long-term goal (‘desire-reason 
dilemma’). After completing a block, they received a total feedback showing the complete 
amount of points they had collected during the respective block. If the participants reacted too 
slowly or pressed the wrong button, the block was aborted and an immediate feedback on the 
screen (“goal not achieved”) was shown.  
All participants completed 80 blocks over the course of two fMRI runs. Both contexts were 
equally often presented. The target cue presentation lasted for 1’500ms. Afterwards, each 
stimulus target was presented for 900ms, leading to a maximum reaction time of 900ms per 
stimuli. For a visual representation of the paradigm see figure 3. 
 
 
FIGURE 3 Graphical presentation of the desire-reason dilemma (DRD) paradigm. The DRD task consists of 
two conditions: the desire and reason context. In both contexts the participants were asked to 
remember two target colors at the beginning of each round, which had to be accepted in the following 
round. Accepting a stimulus was mapped on the left button, whereas rejecting a stimulus was mapped 
on the right button. In the reason context, stimuli that had previously been associated with reward (red 





and all remaining stimuli (non-targets) had to be rejected. A cue at the beginning of each block indicated 
the upcoming condition, i.e. “T” for the reason context and “B” for the desire context. Successfully 
finishing the reason context added 50 points to the subjects’ points account. During the desire context 
for each accepted bonus 10 points were additionally added to the points account. Participants received 
immediate feedback after they pressed their response during the stimulus presentation. The more 
points the subject collected, the more allowance they received for the experiment. The orange star 
indicates the bonus condition in the desire context, which was used for the fMRI analysis. Illustration 
created with Inkscape 0.92.3. 
 
2.3   fMRI data acquisition and analyses 
The experiments of both studies took place in a 3 T MRI scanner (Magnetom TrioTim syngo; 
Siemens Healthcare, Erlangen, Germany) equipped with an eight-channel head coil. For the T1-
weighted anatomical dataset one millimeter isotropic resolution was used. In the fMRI 
experiment, 33 slices in study A and 31 axial slices in study B parallel to the anterior-posterior 
commissure were obtained in ascending acquisition order with a slice thickness of 3mm and a 
gap of 20%. A T2*-sensitive echoplanar imaging (EPI) sequence was applied (study A: TR 
2000ms, echo time 30ms, flipangle 70, field-of-view 192mm; study B: TR 1900ms, echo time 
30ms, flipangle 70, field-of-view 192mm). In study A 251 image volumes were recorded during 
the experiment. In study B, each run contained 185 images, summing up to 370 image volumes 
over two functional runs. Both paradigms were presented via MR-compatible liquid crystal 
display (LCD) goggles. Responses were conducted via a button box and recorded using the 
Presentation Software (Neurobehavioral Systems, Albany, USA). Generation of stimuli and 
triggering of visual stimulation was achieved using the Presentation Software. 
The analysis of the fMRI data was carried out using the software Statistical Parametric Mapping 
(SPM) 8 (Wellcome Trust Centre for Neuroimaging, London, UK). MATLAB served as the 
environment for implementing the toolbox SPM8. Preprocessing steps comprised realignment 
and unwarping, correction for slice time acquisition difference (reference slice 1), co-
registration with the mean EPI image, normalization to Montreal Neurological Institute (MNI) 
space and spatial smoothing with a Gaussian kernel of 9mm full width at half maximum 
(FWHM). Head movement of more than 3 mm led to the exclusion of subjects from the analysis. 
First level analyses were based on a general linear model (GLM) with five regressors (color 
congruent, color incongruent, shape congruent, shape incongruent, oddball) in study A and six 
regressors (target, non-target and reward stimuli for both conditions, i.e. DC and RC) and five 
independent regressors (block and target cues as well as feedback cues in successful and failed 
blocks) in study B. Considering the delay of the BOLD response, the temporal onsets of stimulus 
presentation were convolved with a canonical hemodynamic response function. In both studies 





Linear t-contrasts were defined for the purpose of examining the effects of the different 
experimental conditions. In study A the single subject contrast images consisted of the oddball 
and incongruence stimulus versus implicit baseline, respectively. In study B activation of the 
conditioned reward stimuli in the desire context (see orange star in Figure 3) was compared to 
implicit baseline.  
The second level analyses were carried out with SPM 12 (Wellcome Trust Centre for 
Neuroimaging, London, UK) to compare group effects. In study A, it consisted of the first-level 
“oddball” and “incongruence” contrast images, i.e. oddball and incongruence conditions versus 
implicit baseline. To assess differences between the patient groups and healthy controls the 
one-way ANOVA was applied. Statistically significant effects were determined at a level of 
p<0.05 family-wise error (FWE) corrected for the whole brain. Small volume corrections were 
applied for regions with a priori hypotheses derived from the literature. The significance 
threshold for the small volume correction was p<0.05 FWE-corrected for small-volume 
(Worsley et al., 1996). For the small volume correction, the MNI coordinate of the left 
intraparietal cortex [-36 -60 40] taken from Gruber et al. (2009) was used. Furthermore, new 
findings were reported with a statistical threshold of p < 0.005, uncorrected.  
In study B, the second level analysis comprised single subject contrast images of the response 
to the bonus stimuli in the desire context. A one-way ANOVA was used to determine differences 
between responders versus non-responders in their corresponding psychopharmacological 
treatment group. The findings were reported with a statistical threshold of p < 0.001, 
uncorrected.  
2.4   Behavioral data analyses 
For behavioral data analyses the software package SPSS (IBM SPSS statistics 25) was used. 
Performance was defined as the success rates of the participants. Whether performance and 
mean reaction times data of the patients’ correct trials were normally distributed was checked 
with the Shapiro-Wilk test.  
2.4.1    Study A 
Behavioral data of study A comprised the oddball, incongruence and congruence conditions. 
To guarantee comparability, only incongruent and congruent trials of the shape task were 
considered for the analyses. Table 3 depicts the reaction times and performance of the bipolar, 
schizophrenia and healthy control group.  
The Kruskal-Wallis test was used to identify between-subject differences in performance of 





to compare differences of performances in the congruent, incongruent and oddball condition 
within the respective groups. Wilcoxon tests were conducted to follow up the findings. 
A one-way ANOVA was used to analyze between-subject effects of mean reaction times of the 
bipolar, schizophrenia and healthy control groups. Furthermore, individual one-way ANOVAs 
were applied to identify differences between mean reaction times of the three conditions 
within the respective diagnostic groups. In addition, Gabriel post hoc t-tests were conducted 
to assess group differences in the behavioral data. 
2.4.2    Study B 
In study B, the “correctly accepted bonus stimuli in the desire context” was analyzed according 
to the treatment response division as can be seen in table 4. Patients were organized in atypical 
antipsychotic responders (AA R), atypical antipsychotic non-responders (AA NR), typical 
antipsychotic responders (TA R), typical antipsychotic non-responders (TA NR), aripiprazole 
responders (AP R) and aripiprazole non-responders (AP NR). Success rates and mean reaction 
times were analyzed using separate one-way ANOVAs with the treatment response groups as 
between-subject factor. In addition, Gabriel post hoc t-tests were conducted to assess group 
differences in the behavioral data. 
2.5   Support vector machine analyses 
Multivariate pattern analyses were performed by Dr. Evgeny Gladilin to further validate the 
previous univariate analyses of study B. Therefore, a binary SVM classifier separated 
responders from non-responders. Data analysis was performed with MATLAB 2015a and by 
using a selection of a priori regions of interest (ROIs). 3D whole brain parameter estimates 
obtained from the bonus trials of the desire context were imported as nifti files using the nii 
MATLAB toolbox. The coordinates of target regions initially given in mm were transformed into 
voxel coordinates under consideration of the fMRI voxel resolution and image location. The 
parameter estimates for the predefined coordinates were subsequently extracted and saved in 
a 3 x nVoxels matrix for further analysis. Cohort classification tests were performed with raw as 
well as normalized parameter estimates of the desire versus implicit baseline contrast. 
Normalization was introduced to account for (1) individual differences in the whole-brain 
activity (normalization step 1): 












where b(i) is the beta-score value in the i-th fMRI voxel, as well as (2) to determine the contrast 
between local brain activity of a pathological subject with respect to the reference cohort 





Formula 2 Normalization of the parameter estimates step 2. 
where a(i) denotes the average beta-score in the i-the voxel crossover the reference cohort 
and s(i) the standard deviation of m(i) in the reference cohort.  
The leave-one-out analysis was conducted to test the classifier. The principle scheme of the 
leave-one-out test is as follows: 
1. Exclude the i-th subject from cohort 
2. Train binary SVM classification model for all remaining subjects 
3. Predict the group label of the i-the subject (i.e. pathological or healthy group) using the 
model trained with remaining subjects 
4. Iterate over all subjects (i=1..N) 
5. Calculate the confusion matrix and its derivatives (accuracy, sensitivity, specificity) from 
the real group labels and the results of their model prediction. 
A confusion matrix (also known as error matrix) is a table used for visualization of the 
performance of categorical classifiers in terms of correctly or incorrectly estimated subject 
categories, see an overview in figure 4. Typically, the following performance measures are 
derived from the confusion matrix: accuracy, sensitivity, specificity. Accuracy is defined as the 
ratio between the correctly predicted samples divided by all samples. Correctly classified 
positive samples divided by the sum of correctly classified positive and wrongly negative 
classified samples are specified as sensitivity. The specificity is defined as correctly predicted 
negative samples divided by the sum of correctly negative classified samples and correctly 
predicted negative samples. Additionally, balanced accuracy was calculated to estimate the 
generalization performance of the classifier (Brodersen et al., 2010). The balanced accuracy is 
defined as the arithmetic mean between specificity and sensitivity verifying the balance of the 
dataset. In case of an imbalanced dataset the ordinary accuracy would be oversized whereas 
the balanced accuracy would fall to 50%. Brodersen et al. (2011) stated that in case of 







FIGURE 4 Overview of a standard diffusion matrix.   
Abbreviations: TP= number of true positives; FN= number of false negatives; TN= number of true 





3 RESULTS  
3.1   Behavioral Results 
3.1.1    Study A: Comparison of performance and mean reaction times between patients and 
healthy individuals in the combined oddball-incongruence paradigm 
First, it was examined if performance and mean reaction times within the respective diagnoses 
(bipolar disorder: BD, schizophrenia: SCZ) and healthy control (HC) groups were normally 
distributed by applying a Shapiro-Wilk test. Performance deviated in each condition and 
diagnosis group significantly from normal (oddball: DBD (20)= 0.799, p=0.001; DSCZ (30)= 0.918, 
p=0.024; DHC (40)= 0.628, p<0.001; incongruence: DBD (20)= 0.882, p=0.019; DSCZ (30)= 0.896, 
p= 0.007; DHC (40)= 0.833, p<0.001; congruence: DBD (20)= 0.868, p=0.011; DSCZ (30)= 0.855, p= 
0.001; DHC (40)= 0.760, p<0.001). Therefore, non-parametric tests were applied for the 
following group analyses. Mean reaction times in the oddball condition did not show deviations 
from normal in the three groups (DBD(20)= 0.978, p= 0.905; DSCZ(30)= 0.967, p= 0.469; DHC (40)= 
0.976, p= 0.531). In the incongruence condition, mean reaction times were normally distributed 
in bipolar disorder and healthy controls (DBD(20)= 0.968, p= 0.705; DHC (40)= 0.958, p= 0.141), 
but not schizophrenia (DSCZ(30)= 0.929, p= 0.047). In the congruence condition, mean reaction 
times did not deviate significantly from normal in the patients groups, but were not normally 
distributed in the control group (DBD(20)= 0.982, p= 0.959; DSCZ(30)= 0.958, p= 0.283; DHC (40)= 
0.895, p= 0.001). Table 3 shows performance rates and mean reaction times of the patient 
groups and healthy controls.  
TABLE 3 Overview of the task performance and reaction times of the correct responses of bipolar and 
schizophrenia patients as well as healthy controls 
 Bipolar disorder Schizophrenia Healthy controls 
 mean SD mean SD mean SD 
Performance (%)       
congruence 90.96 8.44 92.05 7.21 96.01 5.03 
oddball 90.67 7.99 89.00 9.15 94.92 8.34 
incongruence  86.53 10.64 84.91 9.31 91.40 9.17 
Reaction time (ms)       
congruence 510.44 90.38 518.60 76.14 461.38 63.52 
oddball 533.63 100.86 545.34 76.39 477.37 69.55 
incongruence  526.12 93.37 530.91 77.35 470.35 62.02 
Abbreviations: ms = milliseconds; SD= standard deviation 
The Kruskal-Wallis test revealed that performance was significantly affected by diagnosis in the 
three conditions (oddball: H(2)=14.841, p=0.001; incongruence H(2)=12.247, p=0.002; 
congruence H(2)=10.800, p=0.005). Follow-up analyses revealed that in the oddball condition 
the schizophrenia and bipolar disorder group demonstrated a similar amount of correct trials 





controls (SCZ vs HC: p=0.001, r=-0.422; BD vs HC: p=0.017, r=-0.356). In the incongruent 
condition, the comparison between bipolar disorder and healthy control groups (p=0.138, r=-
0.258) as well as bipolar disorder and schizophrenia patients (p=1.000, r=0.136) demonstrated 
similar performances, whereas schizophrenia patients performed worse than healthy controls 
(p=0.002, r=-0.408). There was no significant difference between the schizophrenia and bipolar 
group in the congruent condition (p=1.000, r=-0.026). However, both patient groups performed 
significantly worse than healthy controls (SCZ vs. HC: p=0.016, r=-0,331; BD vs HC: p=0.024, r=-
0.343).  
In the next step, the Friedman’s ANOVA was applied to analyze differences between the 
different task conditions within the respective diagnoses groups (BD: χ2(2)= 7.772, p= 0.021; 
SCZ: χ2(2)= 18.200, p < 0.001; HC: χ2(2)= 12.859, p = 0.002). Follow-up analysis revealed 
significant differences between the incongruence and congruence condition in the bipolar 
disorder group (T= 2.763, r= 0.437). Schizophrenia patients performed worse in the 
incongruence than congruence condition (T= 4.248, r= 0.548). The incongruence versus oddball 
(T= -3.440, r= -0.385) as well as the incongruence versus congruence (T= 3.548, r= 0.400) 
conditions showed significant performance differences in the healthy control group. Figure 5 
depicts the results of the performance analyses. 
In the following, a one-way ANOVA was applied to investigate potential differences between 
bipolar disorder and schizophrenia as well as healthy controls in their respective mean reaction 
times. Mean reaction times were significantly affected by diagnosis in each condition (oddball: 
F(2, 89)=7.155, p=0.001, r=0.376, ω2=0.120; incongruence: F(2, 89)=6.681, p=0.002, r=0.369, 
ω2=0.115; congruence: F(2, 89)=5.928, p=0.004, r=0.346, ω2=0.099). Pairwise comparisons 
with adjusted p-values showed that there were no significant differences in the response speed 
between bipolar and schizophrenia patients in the oddball, incongruence and congruence 
condition. However, the schizophrenia and bipolar disorder groups reacted significantly slower 
than the healthy controls in all three task conditions (oddball: HC vs BD: p=0.031, HC vs SCZ: 
p=0.002; incongruence: HC vs BD: p=0.021, HC vs SCZ: p=0.003; congruence: HC vs BD: p=0.048, 
HC vs SCZ: p=0.006).  
Lastly, mean reaction times were compared between the conditions within each participant 
group by applying a repeated-measure ANOVA. Mauchly’s test indicated that the assumption 
of sphericity were not violated in the three groups (BD: χ2(2)=0.119, p= 0.942; SCZ: χ2(2)=0.647, 
p=0.724; HC: χ2(2)=3.081, p=0.214). The mean reaction time of the three diagnoses groups 
varied significantly between the task conditions (BD: F(1.940, 172.645)=27.379, p=0.000; SCZ: 





detected that the reaction times of the oddball and congruence (p=0.001) and incongruence 
and congruence (p=0.017) differed significantly within the bipolar disorder group. Bipolar 
disorder patients responded fastest to the congruent compared to the incongruent and oddball 
stimuli. Mean reaction times of the oddball condition in schizophrenia were significantly 
different from the incongruence (p=0.033) and congruence (p=0.000) conditions. They took 
longer to react to the oddball stimulus than to the congruent or incongruent stimulus. Pairwise 
comparison revealed a significant difference between the congruence versus oddball condition 
(p=0.002) in the healthy individuals’ group. Their response to oddball stimuli took longer than 
to the congruent stimuli. Figure 6 visualizes the results of the mean reaction time analyses.  
 
 
FIGURE 5 Correct trials in percentage of patients and healthy controls during the oddball and incongruence 
condition. Schizophrenia patients demonstrated significantly worse performance in all three conditions compared 
to healthy controls. Bipolar patients performed worse in the oddball and congruence conditions compared to 
healthy individuals. All three groups showed decreased success rates in the incongruence compared to the 
congruence condition. Healthy controls additionally performed worse in the incongruence compared to the 







FIGURE 6 Mean reaction times in milliseconds (ms) of patients and healthy controls during the oddball and 
incongruence condition. Healthy controls responded in all three conditions significantly faster than the patient 
groups. Bipolar patients showed the fastest mean reaction time in the congruent condition. Within the 
schizophrenia group the reaction times varied significantly between the congruent and oddball as well as 
incongruent and oddball condition. Healthy controls demonstrated significantly faster reaction times in the 
congruent compared to the oddball condition.  
 
3.1.2    Study B: Comparison of performance and reaction times between six treatment 
response groups in the DRD paradigm  
In a first step, the Shapiro-Wilk test was used to test if performance data in the “correctly 
accepted bonus stimuli in the desire context” of the six groups (AA R= atypical antipsychotic 
responders; AA NR= atypical antipsychotic non-responders; TA R= typical antipsychotic 
responders; TA NR= typical antipsychotic non-responders; AP R= aripiprazole responders; AP 
NR= aripiprazole non-responders) was normally distributed. The success rate in this context 
was normally distributed in all groups (AA R: D(15)=0.936, p=0.337; AA NR: D(7)=0.880, 
p=0.227; TA NR: D(4)=0.894, p=0.402; AP R: D(7)=0.915, p=0.431; AP NR: D(3)=0.956, p=0.598). 
Secondly, it was tested if the mean reaction times of the six groups varied from the normal 
distribution. Mean reaction times of the “correctly accepted bonus stimuli in the desire 
context” were normally distributed in the following groups: AA NR (D(7)=0.828, p=0.076), TA 
NR (D(4)=0.944, p=0.677), AP R (D(7)=0.836, p=0.091), AP NR (D(3)=0.864, p=0.277). Non-
normally distributed mean reaction times were only found in the AA R group (D(15)=0.793, 





mean reaction times could not be statistically analyzed, as the sample size was too small to gain 
valid results. Table 4 gives an overview of performance and mean reaction times of the six 
responder and non-responder groups. 
Next, by applying a one-way ANOVA it was examined whether significant differences between 
the six groups regarding their correct trials data could be found. There was no significant 
difference between the groups in the “correctly accepted bonus stimuli in the desire context” 
(F(5, 37)=0.898, p=0.494, r=0.35, ω2=-0.014). Furthermore, no significant differences between 
the six groups’ reaction times in the “correctly accepted bonus stimuli in the desire context” 
were detected (F(5, 37)=1.005, p=0.431, r=0.368, ω2=0.001).  
TABLE 4 Task performance and mean reaction times of correct responses of aripiprazole, atypical 
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Abbreviations: ms = milliseconds, SD= standard deviation, R= responder, NR= non-responder, DC= desire context 
 
3.2   fMRI Results 
3.2.1    Study A: Hyper- and hypoactivations of bipolar and schizophrenia patients in the 
combined oddball-incongruence paradigm 
In the following the results of the comparison of brain activations between bipolar and 
schizophrenia patients as well as healthy individuals in the oddball and incongruence condition 
will be presented.  
The analysis of activations in the oddball condition revealed diagnosis-specific hyperactivations 
of bipolar patients compared to healthy controls and schizophrenia patients in frontal regions 
such as the left middle frontal gyrus (MFG), precentral gyrus, OFC and avPFC. These results 
indicate qualitative activation differences between bipolar and schizophrenia patients, i.e. 
diagnosis-specific differences between the patient groups. Furthermore, hyperactivation in the 
right intraparietal cortex in both, bipolar and schizophrenia, patient groups compared to 
healthy individuals was detected. In addition, bipolar patients showed increased activation in 
the right and left intraparietal cortex in relation to schizophrenia patients. Since both 





comparison to healthy individuals it might rather represent a diagnosis-unspecific quantitative 
difference (see table 5 and figure 7).    
TABLE 5 Overview of diagnosis-specific and –unspecific hyperactivations of bipolar and schizophrenia 
patients compared to healthy controls during the oddball condition. 
Abbreviations: L= left, R= right, BD= bipolar disorder patients, SCZ= schizophrenia patients, HC= healthy controls, 
MFG= middle frontal gyrus, OFC= orbitofrontal cortex, avPFC= anteroventral prefrontal cortex  
Activations are reported at p<0.05, corrected for family-wise error rate (FWE); * activation at p<0.005, 
uncorrected; ** activation at p<0.05, FWE-corrected for small volume (6 mm sphere) around a priori coordinates 
from Gruber et al. (2009); [] activation at p<0.05, uncorrected 
Region MNI coordinates 
(t-value) 
BD SCZ HC BD> HC SCZ> HC BD> SCZ 
Diagnosis-specific activation      







[-36 36 30 
(2.58)] 
n.s. 
-36 33 30 
(4.28)* 
L precentral gyrus -45 0 51 
(4.47)* 
-48 -6 54 
(3.06)* 
-48 -9 54 
(7.96) 
-45 9 51 
(2.90)* 
n.s. 






n.s. n.s. -18 39 -12  
(2.84)* 







-27 45 15 
(2.66)* n.s. 
-21 48 6 
(2.81)* 
Diagnosis-unspecific activation      




27 -54 48 
(5.38) 
27 -54 51 
(7.04) 
45 -48 57 
(2.95)* 
[33 -72 57 
(2.38)]  
[42 -42 66 
(2.05)] 












[-33 -69 51 
(2.36)] 
-36 -54 39 
(2.67)*/ -36 -






FIGURE 7 Diagnosis-specific hyperactivations of bipolar patients in comparison to schizophrenia patients. 
Compared to schizophrenia patients, bipolar patients showed hyperactivations in the oddball condition 
in A) the middle frontal gyrus (MFG) (-36 33 30; p=0.005, uncorrected; dotted line), orbitofrontal cortex 
(-24 39 -12; p=0.005, uncorrected; solid line) and B) the precentral gyrus (-45 6 51; p=0.005, 
uncorrected; dotted line) and avPFC (-21 48 6; p=0.005, uncorrected; solid line). 
 
Next, hypoactivations of bipolar and schizophrenia patients were detected in the inferior 
frontal junctions bilaterally, left ventral pathway and pars triangularis. These decreased 
activations were independent of the respective diagnosis. Furthermore, increased deactivation 
of the bipolar patients in the hypothalamus led to significant differences compared to healthy 





TABLE 6 Overview of diagnosis–unspecific hypoactivations and deactivation and thereof resulting 
differences of patients and healthy controls during the oddball condition. 
Abbreviations: L= left, R= right, BD= bipolar disorder patients, SCZ= schizophrenia patients, HC= healthy controls, 
MFG= middle frontal gyrus, OFC= orbitofrontal cortex, avPFC= anteroventral prefrontal cortex  
Activations are reported at p<0.05, corrected for family-wise error rate (FWE); * activation at p<0.005, 
uncorrected; [] activation at p<0.05, uncorrected 
 
FIGURE 8 Hypoactivations of bipolar patients in comparison to healthy controls. Bipolar patients depicted 
hypoactivations compared to healthy individuals evoked by the oddball condition in A) the ventral 
pathway (-33 -66 -3; p=0.005, uncorrected; solid line) and B) the pars triangularis (48 36 6; p=0.005, 
uncorrected; dotted line) and inferior frontal junction (54 0 18; p=0.005, uncorrected; solid line). 
Region MNI coordinates 
(t-value) 
BD SCZ HC BD<HC SCZ<HC BD<SCZ 
Diagnosis-unspecific hypoactivation      
L inferior frontal 
junction 
-42 3 33 
(4.01)* 
-54 3 42 
(3.92)* 
-42 0 33 
(7.17) 
[-48 -3 30 
(2.19)] 
-39 -9 30 
(3.42)* 
n.s. 
R inferior frontal 
junction/ precentral 
gyrus 
42 3 27 
(3.99)* 
 48 3 30 
(3.51)* 
45 3 30 
(7.06)  
54 0 18 
(2.81)* 





L posterior inferior 
temporal cortex/ 
ventral pathway 
-30 -57 -12 
(4.24)* 
-33 -63 -9 
(5.46) 




-33 -66 -3 
(3.30)* 




orbitalis/ R inferior 
frontal gyrus 
n.s. n.s. 
42 36 15 
(4.61)* 
48 36 6 
(2.65)* 
42 42 6 
(3.68)* 
n.s. 
Diagnosis-specific deactivation      
Hypothalamus n.s.  n.s. n.s. 3 -9 -15 
(3.28)* 






In the incongruence condition, patients revealed hypoactivations in similar brain areas as were 
found in the oddball condition. These comprise the inferior frontal junction, ventral pathway 
and pars triangularis. However, brain regions that were hyperactivated in bipolar patients 
during the oddball condition could not be detected during the incongruence condition. In fact, 
both patient groups exhibited hypoactivations in brain regions that were hyperactivated in 
bipolar patients during the oddball condition. Both patient groups exhibited hypoactivations in 
the intraparietal cortex, left MFG, precentral gyrus and avPFC/ OFC compared to the healthy 
individuals. Additionally, decreased activation of bipolar and schizophrenia patients was found 
in the bilateral putamen. 
Finally, increased deactivation of the bipolar patients compared to healthy as well as 
schizophrenia individuals in the hypothalamus/ VTA could be detected (see table 7 and figure 
9).  
 
FIGURE 9 Diagnosis-unspecific hypoactivations of bipolar patients in comparison to healthy controls. 
Bipolar patients demonstrated hypoactivations compared to healthy individuals in the incongruence 
condition in the putamen (-21 3 3; p=0.005, uncorrected; solid line) and the MFG (-33 24 21; p=0.005, 





TABLE 7 Overview of diagnosis-specific and –unspecific hypo- or deactivation and thereof resulting 
differences of patients and healthy controls during the incongruence condition. 
Abbreviations: L= left, R= right, BD= bipolar disorder patients, SCZ= schizophrenia patients, HC= healthy controls, 
IFS= inferior frontal sulcus  
Activations are reported at p<0.05, corrected for family-wise error rate (FWE); * activation at p<0.005, 
uncorrected; ** activation at p<0.05, FWE-corrected for small volume (6 mm sphere) around a priori coordinates 
from Gruber et al. (2009); [] activation at p<0.05, uncorrected 
 
Region MNI coordinates 
(t-value) 
BD SCZ HC BD<HC SCZ<HC BD<SCZ 
Diagnosis- unspecific hypoactivation      
L inferior frontal 
junction 
[-48 6 36 
(2.29)] 
-54 6 36 
(3.63)* / -
48 6 27 
(2.54)** 
-42 0 33 
(7.16) 
-45 -3 30 
(3.63)* 
-42 -3 27 
(3.73)* n.s. 





-42 -72 -6 
(5.59) 




-24 -60 -21 
(3.47)* /-
39 -81 3 
(3.87)*  /-
33 -78 -9 
(3.52) 
-33 -51 -18 
(4.15)*/ -
39 -72 6 
(4.16)* 
[-33 -66 -3 
(2.30)] 




48 3 27 
(5.65) 
45 3 27 
(7.73) 
48 0 30 
(3.53)* 
[51 -6 30 
(1.93)] 
48 3 24 
(2.71)* 
L intraparietal cortex 
[-33 -54 45 
(2.14)] 
-30 -54 45 
(5.19) 
-24 -51 51 
(8.39) 
-24 -51 51 
(3.07)* 
-24 -48 54 
(3.17)* 
n.s. 
R intraparietal cortex/ 
superior parietal lobe 
[30 -54 51 
(1.78)] 
30 -54 48 
(5.59)/ 33 -
66 54 (4.92) 
27 -51 51 
(8.10)  




21 -54 63 
(2.93)* 
[33 -69 57 
(2.15)] / 
[24 -57 51 
(1.74)] 
L precentral gyrus 
[-45 -3 51 
(1.87)] 
-48 -3 54 
(4.15)* 
-48 -6 54 
(8.38) 
-51 -6 51 
(2.99)* 
-48 -9 51 
(3.32)* 
n.s. 
L MFG [-39 33 30 
(1.69)] 
-45 30 36 
(3.01)* 
-27 27 18 
(5.87) 
-33 24 21 
(3.10)* 
[-33 33 15 
(2.52)] 
[-48 27 39 
(2.04)] 
L avPFC / L OFC -18 33 6 
(3.36)* 
-21 33 -3 
(3.38)* 
-27 39 -3 
(6.69) 
-30 42 -3 
(2.87)* 
[-21 39 3 
(2.22)] 
n.s. 
R putamen n.s. n.s. 
27 12 0 
(3.64)* 




27 3 -9 
(2.84)* 
n.s. 
L putamen n.s. n.s. 
-24 6 3 
(5.30) 
-21 3 3 
(2.94)* 




orbitalis/ R inferior 
frontal gyrus 
n.s. n.s. 27 39 0 
(4.77) 
45 36 6 
(4.38)* 
36 42 0 
(2.69)* 
n.s. 
Diagnosis-specific deactivation      
Hypothalamus/ VTA n.s. n.s. n.s. 
[-9 -12 -12 
(3.05)] / 
[12 -6 -18 
(2.54)] 
n.s. 








3.2.2    Study B: Reward-related (de-)activations of the individual treatment response groups 
A univariate ANOVA revealed significant differences in brain activation between treatment 
responders and non-responders in the desire context of the individual treatment groups. The 
aripiprazole responders exhibited stronger deactivation of the bilateral MTG (MNI coordinates: 
-66 -36 0 (L) and 57 -9 -21 (R)), left precuneus (MNI coordinates: -9 -63 42), angular gyrus (MNI 
coordinates: -48 -66 18), occipital cortex (MNI coordinates: -30 -78 15), superior frontal gyrus 
(MNI coordinates: -24 12 39) and right hippocampus (MNI coordinates: 21 -24 -12), pregenual 
anterior cingulate cortex (MNI coordinates: 12 60 15), frontal inferior orbital gyrus (MNI 
coordinates: 45 39 -9) and amygdala (MNI coordinates: 24 3 -15). Comparisons between 
atypical antipsychotic responders and non-responders and between typical antipsychotic 
responders and non-responders only revealed low-threshold differences in brain areas such as 
the right MTG, hippocampus and left precuneus (MNI coordinates AA R> AA NR: 63 -6 24 (MTG); 
TA R > TA NR: 24 -33 -12 (hippocampus), 57 -3 -15 (MTG), -9 -51 36 (precuneus)).  
In addition, stronger activations of the aripiprazole responders compared to non-responders 
were found in the right avPFC (MNI coordinates: 39 51 6) and ventral striatum (MNI 
coordinates: 9 9 -6). As can be seen in table 8, it was differentiated between activation-induced 
and deactivation-initiated differences. Figure 10 shows activation differences between 
aripiprazole responders and non-responders. Only low-threshold differences between atypical 
responders and non-responders and between typical responders and non-responders could be 
found in the avPFC (MNI coordinates AA R> AA NR: -45 45 -9; TA R > TA NR: -36 45 6 (L), 39 45 
6 (R)). 
To further validate these findings, an interaction contrast ((AP R – AP NR)- ((AA R | TA R) - (AA 
NR | TA NR)) was used to examine the results. The interaction contrast supported the effects 
found in the comparison of aripiprazole responders and non-responders by revealing significant 
increased activations in the same brain regions, i.e. bilateral avPFC and ventral striatum. 
Furthermore deactivation-induced differences were consistently found in the precuneus, 
pregenual anterior cingulate cortex, angular gyrus, subcortical areas, such as the right 
hippocampus, right amygdala, as well as temporal and parietal brain regions (indicated in more 





TABLE 8 Reward related brain (de-)activation in the desire condition in responders (R) compared to 
non-responders (NR) of aripiprazole (AP), atypical (AA) and typical (TA) antipsychotic treatment.  
Abbreviations: L= left, R= right, AP R= aripiprazole responders, AP NR= aripiprazole non-responders, AA R= atypical 
antipsychotics responders, AA NR= atypical antipsychotics non-responders, TA R= typical antipsychotics 
responders, TA NR= typical antipsychotics non-responders, avPFC= anteroventral prefrontal cortex, MTG= middle 
temporal gyrus, pgACC= pregenual anterior cingulate cortex | Activations are reported at p<0.001, uncorrected; 
* activation at p<0.005, uncorrected; ** activation at p<0.05, uncorrected 
Region AP R > AP NR AA R > AA NR TA R > TA NR (AP R- AP NR)> 
((AA R | TA R)- 
(AA NR | TA NR)) 
MNI coordinates (t-
value) 
    
Activation  
L avPFC -42 45 3 (2.56)** -45 45 -9 (1.93)** -36 45 6 (1.82)** -45 51 3 (2.23)** 
R avPFC 39 51 6 (3.55) n.s. 39 45 6 (2.44)** 45 54 0 (3.66) 
L ventral striatum -6 9 -6 (2.92)* n.s. n.s. -6 9 -6 (2.76)* 
R ventral striatum 9 9 -6 (4.12) n.s. n.s. 9 9 -6 (3.96) 
Deactivation  
R hippocampus 21 -24 -12 (3.75) n.s. 24 -33 -12 (2.09)** 18 -21 -12 (4.24) 
L MTG -66 -36 0 (3.79) n.s. n.s. -66 -36 0 (3.58) 
R MTG 57 -9 -21 (3.87) 63 -6 -24 (2.74)* 57 -3 -15 (2.29)** 60 -3 -21 (2.10)** 
L precuneus -9 -63 42 (4.45) n.s. -9 -51 36 (1.98)** -12 -60 39 (3.41) 
R pgACC 12 60 15 (4.83) n.s. n.s. 12 60 15 (3.87) 
L angular gyrus -48 -66 18 (4.62) n.s. n.s. -45 -66 18 (4.77) 
L cuneus -18 -63 18 (4.82) n.s. n.s. -18 -63 18 (4.81) 
L occipital cortex -30 -78 15 (4.38) n.s. n.s. -30 -78 12 (3.76) 
R frontalinferior 
orbital gyrus 
45 39 -9 (4.89) 45 39 -18 (3.03)* n.s. 45 39 -9 (4.55) 
R amygdala 24 3 -15 (4.30) n.s. n.s. 24 3 -15 (3.50) 
L superior frontal 
gyrus 






FIGURE 10 Activation differences between aripiprazole responders and non-responders in the DRD paradigm. Aripiprazole responders showed stronger activations 
(red) compared to the non-responders in A) the ventral striatum (9 9 -6, t= 4.12, dashed line) and anteroventral prefrontal cortex (39 51 6, t= 3.55, dotted line). 
Non-responders revealed deactivations (blue) in A) the occipital lobe (-30 -78 15, t= 4.38, solid line), B) amygdala (24 3 -15, t= 4.30, dashed line), pregenual anterior 
cingulate cortex (12 60 15, t= 4.83, solid line), frontalinferior orbital gyrus (45 39 -9, t= 4.89, dotted line), C) hippocampus (21 -24 -12, t= 3.75, dashed line), 




3.3   SVM results  
3.3.1    Study B: Treatment response prediction using SVM analyses  
Bain regions (i.e. fMRI voxels) identified by the univariate analyses of study B (see table 8) were 
used for the training of a multivariate prediction model of the patients’ treatment response to 
aripiprazole using the linear SVM classifier as described in Section 2.5. 
Two SVM analyses were separately performed for two groups of fMRI voxels that demonstrated 
either elevated or reduced activation during the DRD paradigm in aripiprazole responders in 
comparison to non-responders, see table 8 (activation vs deactivation). 
The first SVM analysis used parameter estimates of stronger activated regions, i.e. the avPFC 
and ventral striatum (L/R) to predict treatment response of patients being treated with 
aripiprazole, atypical or typical antipsychotics. For these regions, mean balanced accuracies 
ranged between 53.33% and 54.17% in the aripiprazole, atypical and typical antipsychotic 
groups. These accuracy measures led to non-significant results in all three groups (p>0.05) 
indicating no reliable prediction of treatment response.  
The second model based on parameter estimates of regions found to be stronger deactivated 
in aripiprazole non-responders, was used to predict treatment response of the patients 
respectively of their corresponding treatment group. SVM leave-one-out tests revealed that 
information from the deactivation coordinates enabled significantly more accurate predictions 
of aripiprazole treatment: accuracy=100%, sensitivity=100%, specificity=100%, balanced 
accuracy=84.49% (p-value=0.002), see table 9. In contrast, the results of the leave-one-out test 
for typical and atypical antipsychotics indicated rather poor predictability of the SVM 









TABLE 1 Predictions of treatment response after treatment with aripiprazole, atypical and typical 
antipsychotics.   
 Aripiprazole Atypical antipsychotics Typical antipsychotics 
 Activation Deactivation Activation Deactivation Activation Deactivation 
Accuracy 60.00% 100% 63.64% 54.55% 66.67% 33.33% 
Sensitivity 33.33% 100% 28.57% 42.86% 100.00% 50.00% 
Specificity 33.33% 100% 40.00% 33.33% 66.67% 50.00% 
Balanced accuracy* 53.33% 84.49% 54.90% 51.63% 54.17% 37.48% 
p value* 0.405  0.002 0.300 0.437 0.373 0.821 
*: calculated according to Brodersen et al., 2010 
Finally, boxplots of parameter estimates at their local minima and maxima were prepared to 
visualize the influence of the different brain regions on the SVM algorithm (see figure 11). Three 
very influential brain regions were selected to outline the great variance between the six 
groups. This depiction underlines the severe effect of the aripiprazole non-responders’ 








FIGURE 11 Mean parameter estimates distribution of the treatment response groups. In all three brain 
regions (A: left middle temporal gyrus (MTG), B: right amygdala, C: left angular gyrus) the aripiprazole 
non-responder group showed the lowest mean parameter estimates indicating strong deactivation. 





This thesis aimed to investigate pathomechanisms of bipolar and schizophrenia patients. It is 
commonly observed that these disorders exhibit disturbed processing in various cognitive as 
well as reward related tasks. To improve diagnosis and treatment of both psychiatric disorders, 
it is necessary to better understand the functional changes in relevant brain regions. Study A 
demonstrated diagnosis-(un)specific differences in the frontoparietal attention network of 
bipolar disorder and schizophrenia patients during a combined oddball-incongruence 
paradigm. In study B, the application of the DRD paradigm revealed activation abnormalities in 
frontostriatal brain areas of aripiprazole non-responders compared to aripiprazole responders. 
Moreover, an SVM algorithm used the parameter estimates of deactivation coordinates from 
the univariate analysis to predict their treatment response.  
The development of biomarkers derived from activation abnormalities within reward- or 
attention-associated networks offers the chance for individualized and efficient diagnosis and 
treatment of patients. The results of study A demonstrated diagnosis-specific frontal 
hyperactivations of bipolar disorder individuals, which brought new insights regarding task 
difficulty- dependent disturbances within their attention network. The findings suggest bipolar 
disorder-specific compensation mechanisms that might represent a novel biomarker for 
diagnosis. In study B, deactivations of aripiprazole non-responders in brain regions such as the 
hippocampus, amygdala, anterior cingulate cortex etc. during the DRD paradigm indicated that 
they could potentially be valuable for predicting treatment response. This is the first time that 
brain deactivation patterns resulting from a reward-related paradigm, were able to classify 
patients as responders or non-responders of aripiprazole treatment. The investigation of 
pathomechanisms of bipolar disorder and schizophrenia might hence be useful to further 
elaborate their predictive potential.  
In the following sections, the results of the individual studies will be discussed in detail. 
Afterwards there will be a combined conclusion of both studies, followed by a discussion of 
potential limitations and prospective ideas. 
 
4.1   Study A: Diagnosis-(un)specific hyper- and hypoactivations of bipolar and schizophrenia 
patients 
Study A compared the functional responses underlying attentional processes induced by 
oddball and incongruence stimuli in bipolar and schizophrenia patients. New insights were 
gained with regard to the exertion of cognitive control. The results revealed corresponding 
brain activation patterns during the presentation of the oddball and incongruence stimuli, 




schizophrenia patients as well as healthy controls. The pathophysiological alterations found in 
the patients' brain activation seem to be associated with the task difficulty. 
Diagnosis-specific hyperactivations of bipolar patients compared to schizophrenia and healthy 
individuals were found in frontal brain regions such as the left avPFC, OFC, precentral gyrus and 
MFG during the oddball condition. Since these hyperactivations could be specifically assigned 
to bipolar patients, they seem to represent a qualitative pathophysiological difference between 
bipolar disorder and schizophrenia. Taking the behavioral results into account, bipolar patients 
performed significantly worse and slower than healthy controls but not schizophrenia patients 
in the oddball condition. Therefore, hyperactivations of the bipolar group might reflect a 
compensation mechanism trying to balance potential deficits. Similar studies that investigated 
cognitive control processes already reported increased activation in bipolar patients compared 
to healthy controls. In an experiment by Fleck et al. (2011), greater activation in the frontal 
cortex of mixed episode bipolar disorder patients compared to healthy controls was shown 
during a Go/ No-Go task. This is in line with another study, showing enhanced activation in the 
PFC of bipolar patients in comparison to healthy individuals during a Multi-Source Interference 
Task (Gruber et al., 2017). The authors of both studies concluded that a lack of cognitive control 
might lead to abnormal activation patterns while solving cognitive tasks. It was hypothesized 
that brain regions linked to emotion processing might be hyperactivated in bipolar disorder and 
hence interfere with efficient processing of novel stimuli. However, it is important to note that 
the majority of fMRI studies examining cognitive control processes in bipolar disorder 
demonstrated reduced activation in prefrontal brain structures compared to healthy controls 
(Frangou et al., 2006; Joshi et al., 2016; Kronhaus et al., 2006; Penfold et al., 2015). A potential 
explanation for this discrepancy could be the varying cognitive load of the different 
experimental tasks. Most of the cognitive control experiments might overstrain bipolar patients 
leading to reduced activation in their prefrontal control network. This assumption will be 
discussed in more detail in a later paragraph. The oddball condition in this study, however, 
might be challenging enough to induce behavioral deficits, but not demanding enough to cause 
hypoactivations. Bipolar patients in this study might compensate for the novelty effect of the 
oddball stimulus by hyperactivating frontal brain areas.  
While bipolar and schizophrenia patients demonstrated comparable performance deficits, i.e. 
significantly worse performance than healthy controls, their activation in frontal brain regions 
differed significantly in the oddball condition. Variations in the underlying compensation 
mechanisms could be a possible cause for the activation differences. Bipolar patients might 
have recruited frontal brain regions such as the OFC and avPFC to try and maintain the novelty 
detection processing. Schizophrenia patients, on the other hand, might not activate prefrontal 
regions to the same extent. A prior study already reported increased activation in bipolar 
compared to schizophrenia patients during a neurocognitive fMRI task (McIntosh et al., 2008). 




addition, hypoactivation of ultra-high-risk schizophrenia individuals during a visual oddball task 
was reported in the MFG and inferior frontal gyrus (Morey et al., 2005). They linked their results 
to the deficient dopamine transmission of schizophrenia patients, resulting in dopamine-
induced enhanced salience to external stimuli. Therefore, even prodromal schizophrenia 
individuals would have greater problems with the processing of task-relevant features (Morey 
et al., 2005).  
Another possible reason for differences in cognitive control processing might result from 
differently impaired cognitive performance levels. Various studies and meta-analyses of 
cognitive processes in bipolar disorder and schizophrenia ascribe greater cognitive dysfunction 
to schizophrenia patients and intermediate deficits to bipolar disorder (Altshuler et al., 2004; 
reviewed in Krabbendam et al., 2005; Lynham et al., 2018; reviewed in Stefanopoulou et al., 
2009). Melcher et al. (2014) examined the cognitive performance of bipolar and schizophrenia 
patients in the same combined oddball-incongruence task. They reported an overall greater 
cognitive impairment in schizophrenia patients in both, the oddball and incongruence, 
conditions. It can be hypothesized that these cognitive disturbances also affect functional 
responses. Therefore, compensatory mechanisms might be less pronounced in schizophrenia 
compared to affective disorders leading to reduced activation in frontal brain areas.  
In this study bipolar patients exhibited greater activation in the intraparietal cortex compared 
to schizophrenia patients and healthy controls. However, schizophrenia individuals also 
presented increased, but low-threshold, hyperactivation compared to the controls. Bipolar 
patients might integrate frontal and intraparietal regions and hence compensate for their 
cognitive deficits whereas schizophrenia patients might only recruit the intraparietal cortex as 
compensatory support. As a result, bipolar and schizophrenia patients vary in their quantitative 
level of compensation. This mechanism seems to be consistent, as the hyperactivation of 
schizophrenia patients in the intraparietal cortex during the same combined oddball-
incongruence task was already shown by Wolter et al. (2016). The difference in the statistical 
power might result from greater heterogeneity within the schizophrenia group due to the 
increased sample size in the current study. It has been shown multiple times that schizophrenia 
comprises a great spectrum involving multiple symptomatic features (Lewandowski et al., 
2014). Therefore, it might not be surprising to find quantitative differences in the functional 
data. 
So far, these results hint at different compensatory strategies and capacities of bipolar and 
schizophrenia patients. Whereas bipolar patients seemed to use a frontoparietal network to 
counterbalance deficits in the processing of the oddball stimulus, schizophrenia patients might 
have deficits in their compensatory mechanisms and only showed low threshold 




In the next section, hypoactivations of the bipolar and schizophrenia group will be examined 
more closely. Both patient groups exhibited hypoactivations in the frontal areas and the ventral 
pathway.  
The ventral pathway plays a central role in the processing of visual stimuli as it connects the 
primary visual cortex to temporal brain areas (Mishkin, 1982). Conjunctions of temporal regions 
with limbic and frontal networks facilitate the integration of emotional or experiential factors 
in the processing of feature dimensions (Kuypers et al., 1965; reviewed in Mishkin et al., 1983; 
Turner et al., 1980). In the current study, healthy individuals seem to identify visual objects 
without difficulties and without interference of other implicit processing networks. Patients, 
however, might experience more malfunctions due to the influence of parallel processing of 
other cognitive requirements. Therefore, patients’ hypoactivations in the ventral pathway 
might indicate aberrant processing of visual stimuli. The current literature mostly supports this 
idea as various studies demonstrated hypoactivations in the visual cortex and temporal areas 
of schizophrenia patients compared to healthy controls during visual perception tasks (Green 
et al., 2009; Lee et al., 2019; Sehatpour et al., 2010). In contrast, Silverstein et al. presented 
hyperactivation in the lateral occipital complex of schizophrenia patients in an object 
recognition task in comparison to healthy controls (Silverstein et al., 2015). Consequently, the 
pathomechanisms of schizophrenia regarding vison processing seem not be completely 
understood, yet. 
There are only few studies examining visual processing in bipolar disorder. Shaffer et al. 
demonstrated decreased brain activation in visual areas of manic and depressed bipolar 
patients compared to healthy controls (Shaffer et al., 2018). Since they also found functional 
differences between mood states, i.e. manic, depressed and euthymic, they assumed visual 
processing activation to be a state marker for bipolar disorder. Furthermore, fMRI adaptation 
in the visual cortex seems to be impaired in bipolar patients (Lee et al., 2019). While healthy 
controls demonstrated reduced functional response to the repeated presentation of the same 
objects in the visual cortex, bipolar patients did not present this adaptation. Another non-fMRI 
study revealed deficits of bipolar patients compared to healthy controls only in late stages of 
visual processing, i.e. higher involvement of perceptual and attentional processes (Jahshan et 
al., 2014). Schizophrenia patients, on the other hand, demonstrated impairments in all stages 
of visual processing (Jahshan et al., 2014). This is in line with the aforementioned hypothesis of 
greater cognitive dysfunction and a lack of compensatory mechanisms of schizophrenia 
patients compared to bipolar patients. However, in sum, the underlying pathomechanisms 
responsible for abnormalities in visual processing of bipolar and schizophrenia seem not to be 
fully resolved, yet.  
Diagnosis-unspecific hypoactivations of bipolar and schizophrenia patients compared to 
healthy controls were further detected in the inferior frontal junction. The inferior frontal 




(Asplund et al., 2010; Tamber-Rosenau et al., 2018). Tamber-Rosenau et al. in particular 
emphasized its involvement in attention shifting. Consequently, deficits in attention shifting 
from novel to relevant stimuli might lead to reduced activation. In line with this, various studies 
reported deficiencies of bipolar and schizophrenia patients in shifting their attention (Bozikas 
et al., 2014; Di Giorgio Silva et al., 2016; Melcher et al., 2014).  
Taken together, results from the oddball condition showed diagnosis-specific hyperactivations 
of bipolar patients in frontal regions as well as diagnosis-unspecific hyperactivations of bipolar 
and schizophrenia patients compared to healthy controls in the intraparietal cortex. 
Furthermore, both patient groups revealed hypoactivations in the inferior frontal junctions and 
ventral pathway. A possible explanation might be compensatory mechanisms, including the 
involvement of frontal structures, to balance deficiencies within their cognitive control 
network. It seems as if this process might be more pronounced in bipolar disorder, as 
schizophrenia patients only recruited the intraparietal cortex to compensate for their cognitive 
impairments.  
In this next section, brain activation differences between bipolar and schizophrenia as well as 
healthy individuals in the incongruence condition will be discussed. The incongruence condition 
has been shown to induce response conflicts and to interfere with executive control (Gruber et 
al., 2009; Melcher et al., 2014). In the current study, most of the brain areas that were activated 
in the oddball condition also showed activation in the healthy control group during the 
incongruence condition. These comprise the inferior frontal junction, ventral stream, 
intraparietal cortex, precentral gyrus, putamen and superior frontal sulcus. These 
frontoparietal regions and the ventral pathway have repeatedly been shown to be activated 
during oddball and incongruence conditions in healthy individuals (Corbetta et al., 2000; 
Falkenberg et al., 2011; Hopfinger et al., 2000; Rusiniak et al., 2013; Strobel et al., 2008; van 
Veen and Carter, 2005; Wolter, 2016; Zysset et al., 2001). The results of these studies underline 
the reliability of oddball and incongruence effects. Therefore, underlying mechanisms such as 
selective attention, the processing of rare and interference-inducing stimuli seem to be 
replicable and stable across different tasks.  
The comparison between the patient groups and healthy controls revealed hypoactivations in 
regions that were also hypoactivated during the oddball condition. These comprise the inferior 
frontal junction, ventral pathway and right pars triangularis. It can be concluded that bipolar 
and schizophrenia patients share potentially pathophysiological hypoactivations in the 
processing of the oddball stimulus and the response conflict induced by the incongruence task.  
Additional brain areas such as the avPFC, MFG, intraparietal cortex and superior frontal gyrus 
revealed diagnosis-unspecific hypoactivations of the patient groups during the incongruence 
condition. As these brain regions were hyperactivated in bipolar patients during the oddball 




attentional capacities. Taking the behavioral data into account, it can be observed that healthy 
controls had greater difficulties in the incongruence condition leading to significant differences 
in their performance compared to the congruent and oddball condition. Due to the fact that 
the incongruence condition involves another dimension, i.e. an interference-inducing color 
dimension, more information needs to be processed, leading to an increased cognitive 
demand. As a result, enhanced mental load could cause a decrease in their task accuracy. Mean 
reaction times of the three groups in the oddball condition indicate a slightly delayed response 
potentially due to the saliency effect of the oddball stimulus. All in all, the mental load of the 
incongruence condition might expect too many resources of the two patient groups. The 
compensation mechanism of the frontoparietal network which could be seen in the bipolar 
patients during the oddball condition might not be sufficient. As a result, the compensatory 
strategy might collapse resulting in hypoactivations across the relevant brain regions. A possible 
explanation for this effect was originally proposed for contradictory effects in the working 
memory load of psychiatric patients. Multiple studies have published data supporting this 
model (Callicott et al., 1999; Jansma et al., 2004; Karlsgodt et al., 2007; reviewed in Manoach, 
2003; Mendrek et al., 2004). It describes a linear correlation between task difficulty and the 
functional response curve, which is capped at a certain turning point and afterwards leads with 
further increasing difficulty to a reduction in the neurophysiological response resulting in an 
inverted U-shaped curve. In psychiatric patients this curve has been shown to be shifted to the 
left, as they often suffer from cognitive impairment. Consequently, the comparison between 
patients and healthy controls shows hyperactivations in patients during easier tasks, e.g. the 
oddball condition, but hypoactivations in tasks that require more mental capacity, e.g. the 
incongruence condition. In the current study, bipolar patients might have recruited the 
frontoparietal network to accomplish the oddball condition. However, in the incongruence 
condition their attention load was exceeded, leading to reduced functional response. 
Schizophrenia patients demonstrated hyperactivation during the oddball task and 
hypoactivation during the incongruence task in the intraparietal cortex, suggesting an overall 
more impaired attention processing system with even greater deficits during the presentation 
of the incongruent stimuli. 
The putamen is another region that presented diagnosis-unspecific hypoactivations in bipolar 
and schizophrenia. It is part of the striatum which has been shown to be altered in 
schizophrenia and bipolar disorder multiple times (reviewed in McCutcheon et al., 2019; Trost 
et al., 2014). A meta-analysis by Minzenberg et al. compared brain activations in the cognitive 
control network of healthy controls and schizophrenia patients and revealed decreased 
activation in the right putamen of schizophrenia patients (reviewed in Minzenberg et al., 2009). 
Furthermore, a recent meta-analysis by Tian et al. demonstrated a lack of activation in the 
ventral striatum of bipolar patients during executive functioning tasks (reviewed in Alustiza et 




functioning and hence might also be involved in pathophysiological processes of bipolar 
disorder and schizophrenia. 
Another finding affecting both, the oddball and incongruence, conditions was a diagnosis-
specific deactivation of the bipolar disorder patients in the hypothalamus. Over 80 years ago it 
was proposed that the limbic system projects to the hypothalamus and thereby possibly 
initiates emotion expression (MacLean, 1949; Papez, 1937). Later on, also outputs from 
prefrontal brain regions were discovered to innervate the hypothalamus in primates (Barbas et 
al., 2003; Öngür et al., 1998). Lesion studies of the human ventromedial PFC confirmed this 
connection as they found attenuation of basic somatic states in response to emotional stimuli 
(Damasio et al., 1990). Additionally, anomalies have been found in the hypothalamus of bipolar 
patients. On the one hand, a decreased overall volume of the hypothalamus was shown in 
structural MRI studies (Bielau et al., 2005). On the other hand, bipolar disorder has been linked 
to a dysfunctional HPA axis which is involved in the stress response, somatic processes as well 
as mood (Watson et al., 2006). Furthermore, the hypothalamic suprachiasmatic nucleus 
controls the circadian clock via the secretion of melatonin. Taking into account that one major 
symptom of bipolar disorder is a drastically reduced need to sleep, it is hypothesized that the 
function of the hypothalamus regulating the day-night-rhythm might be disturbed (Lewy et al., 
1985; Zhou et al., 2001). In line with this argumentation, bipolar-specific deactivation in the 
hypothalamus might be related to an overall disruption in this brain area and might not be 
specific for the processing of cognitive control. 
Taken together, these results revealed activation differences between patients and healthy 
controls during the processing of the oddball and incongruence effects suggesting differential 
compensation mechanisms as well as impairment severity in attentional processing of the two 
psychiatric disorders. Whereas bipolar patients recruited frontoparietal brain areas to 
compensate for potentially deficits in the oddball task, schizophrenia patients showed 
hyperactivation exclusively in the intraparietal cortex. However, the incongruence condition 
seemed to involve greater cognitive load compared to the bipolar disorder resulting in 
frontoparietal hypoactivations of both patient groups. Consequently, both tasks seem to 
involve the activation of similar brain regions, though evoke only partially shared responses in 
the two patients’ groups. Future studies will be necessary to further investigate differences in 
the pathomechanisms of bipolar disorder and schizophrenia regarding cognitive control 
processes.  
4.2   Study B: Potential biomarkers to predict treatment response of aripiprazole 
The main finding of study B was that an SVM algorithm could predict treatment response to 
aripiprazole based on task-induced deactivation differences between responders and non-
responders. Aripiprazole non-responders demonstrated altered activation patterns in the right 




superior frontal gyrus providing the data for a successful prediction. These results indicate that 
task-induced deactivations in regions linked to the default mode network (DMN) might be 
reliable markers to predict treatment response for aripiprazole administration.  
In general, it might be of interest to give a short overview of the reward-related DRD paradigm 
applied in this study. The DRD paradigm aims to examine the dopaminergic reward system and 
networks connected with its processing. By associating a strong bond between specific color 
stimuli and a reward feedback it provokes activation in dopaminergic brain regions, i.e. the VTA, 
as well as dopaminergic innervated areas such as the ventral striatum. Its reliability has been 
proven in various studies which reported consistently activation of the VTA and ventral striatum 
during the bonus stimuli presentation in the desire context (Diekhof and Gruber, 2010; Diekhof 
et al., 2012; Richter et al., 2015; Trost et al., 2014). The DRD paradigm was also used to detect 
differences in the reward processing of psychiatric patients. A recent study applying the DRD 
paradigm, revealed significant hypoactivation of schizophrenia patients compared to healthy 
controls in the avPFC as well as hyperactivation in the left ventral striatum (Richter et al., 2015). 
Another study detected hypoactivation in the ventral striatum of bipolar disorder patients 
during the DRD paradigm (Trost et al., 2014). Since bipolar disorder and schizophrenia are both 
linked to dopaminergic dysfunction (reviewed in Ashok et al., 2017; reviewed in McCutcheon 
et al., 2019), it was of great interest to find out whether the utilization of this paradigm can 
identify activation differences in reward-related brain areas between responders and non-
responders. Indeed, results from this thesis indicated activation anomalies in reward processing 
associated brain regions such as the ventral striatum of aripiprazole responders and non-
responders. However, it was not possible to make predictions about the success of the 
respective psychopharmacological treatment groups by applying data of these activation 
anomalies to the SVM algorithm.  
In contrast, deactivations of the aripiprazole non-responders were able to predict treatment 
response. Deactivation of the hippocampus during the DRD paradigm might result from 
impaired dopaminergic modulation. Due to its dopaminergic input (Gasbarri et al., 1997) the 
hippocampus is known to mediate reward processing and plays an important role in 
reinforcement learning (Stevens et al., 1991). Therefore, disruptions of dopaminergic 
transmission in the hippocampal area, as previously found in schizophrenia (reviewed in 
Heckers and Konradi, 2010) and affective disorder patients, might result in decreased 
activations in the hippocampus during reward-related tasks. Furthermore, the administration 
of rewarding stimuli has been associated with improved memory consolidation (Messier and 
White, 1984). However, responding to the steady color change does not require long-term 
memory performance. Conversely, the activation of memory processes might interfere with 
the participants’ reaction to constantly changing cue stimuli. Consequently, deactivation of the 





In addition, aripiprazole non-responders revealed deactivations in the right pgACC, left 
precuneus and angular gyrus in during the desire context of the DRD paradigm. These brain 
regions have been associated with the DFM. In general, a lot of hypothesis-driven fMRI studies 
aim to induce activation patterns in brain regions associated with their hypothesis by applying 
cognitive paradigms which involve specific stimuli that supposedly elicit the hypothesized 
response. However, it was discovered already in the 1990s that subjects also show task-induced 
deactivation apart from the expected responses to certain stimuli (Haxby et al., 1994; 
Kawashima et al., 1995). Back then, these deactivations were thought to present a brain 
mechanism suppressing unnecessary background activation to enhance performance in brain 
regions involved in the task’s execution (reviewed in Binder, 2012). Shulman et al. (1997) 
demonstrated in a meta-analysis that a lot of the task-induced decreases in blood flow were 
found in the same regions across various tasks. The most common explanation for this effect 
proposes that deactivations result from the redistribution of attentional activity from internal 
processes to task-relevant information. Therefore, these deactivations might be unspecific and 
overlap across various cognitive tasks as they might not be induced by specific stimuli but rather 
represent some form of suppression of processes that take place during “resting” or passive 
states.  
Taken together, task-induced deactivations might be a marker for aripiprazole non-response. 
It is not clear why aripiprazole non-responders deactivated more than aripiprazole responders. 
As no significant differences in their behavioral data could be detected, it seems as if these 
differences might be based on specific pathomechanisms linked to DMN processes. 
Consequently, it could be proposed that corresponding subgroups might not respond very well 
to the dopamine partial agonist aripiprazole. They might, however, benefit from treatment with 
first- or second-generation antipsychotics.  
Results of this thesis suggest the existence of subgroups within the schizophrenia-bipolar 
disorder- spectrum that have greater or fewer dysfunctions in the mesolimbic reward system 
as well as the DMN resulting in activation differences. These subgroups might also respond 
differently well to antipsychotic medication. Therefore, their subgroup-specific activation 
patterns might represent biomarkers for individual treatment response. This is in accordance 
with a study by Bak et al. (2017) who tried to identify subgroups within a sample of 
antipsychotic-naïve first-episode schizophrenia patients. In their study, a Gaussian mixture 
model with electrophysiological and cognitive data of the patients differentiated two 
subgroups after six weeks of treatment with amisulpride. Additionally, they investigated the 
correlation between PANSS scores and the two subgroups by applying SVM analyses. Even 
though univariate comparisons of demographic or clinical data at baseline did not yield any 
differences, SVM analyses were able to predict the treatment response with an accuracy of 
74.3% (Bak et al., 2017). In their conclusion, they called for multivariate and multimodal 




executive function task to identify subgroups of schizophrenia. The authors detected three 
clusters of schizophrenia patients that differed in their cognitive capacities (Carruthers et al., 
2019). Similar results have also been found in bipolar disorder (Kollmann et al., 2019; Russo et 
al., 2017). In addition, structural differences in brains of bipolar patients have been found, 
indicating subtypes within the same disease (Sarrazin et al., 2018). These results underline the 
heterogeneity within the individual diagnoses, but also across schizophrenia, schizoaffective 
and bipolar disorder. They seem to form subclusters according to other scales and independent 
of their specific diagnosis. In addition, as mentioned before, the border between bipolar 
disorder and schizophrenia is fluent and sometimes bipolar disorder is also referred as a milder 
version along the schizophrenia spectrum (Argyelan et al., 2014; Costafreda et al., 2011; Crow, 
1986; reviewed in De Peri et al., 2012; Hill et al., 2013; Krishnadas et al., 2014). Therefore, it 
seems not surprising to find differences in the reward and DMN processing between the 
aripiprazole response groups. Consequently, the heterogeneity across the diagnoses might also 
affect the response to psychopharmacological treatment. This study demonstrated activation 
differences in mesolimbic areas and deactivations in DMN-associated brain regions. These 
results hint at different DMN- or reward-related pathophysiologies of the treatment groups 
which in consequence urge for differential treatment.  
It is of great interest to understand the neurobiological correlates of the (de)activation 
differences between aripiprazole responders and non-responders in the reward condition of 
the desire context. A potential reason might be that the previously discussed functional 
heterogeneity within schizophrenia and bipolar patients is based on molecular, genetic and 
structural differences that influence the response to psychopharmacological medication. This 
is supported by a recent study reporting a subthreshold impact of epigenetic dopamine D2 
receptor modifications on the response to aripiprazole treatment (Miura et al., 2018). They 
hypothesized that epigenetic factors might influence dopaminergic transmission and hence 
affect treatment response of schizophrenia patients. In line with this, another study found that 
the genetic polymorphism of a dopamine metabolizing protein influenced the improvement of 
schizophrenia patients treated with aripiprazole (Kaneko et al., 2018). In consequence, 
(epi)genetic variations causing alterations in the dopaminergic transmission of schizophrenia 
or bipolar patients might become visible as functional differences within the reward processing 
network. In addition, genetic polymorphisms of DAT affected the influence of aripiprazole on 
cue-elicited ventral striatum activation (Schacht et al., 2018). This further supports the idea 
that neurobiological alterations of dopamine release in patients might be a predictor for 
treatment response. As proposed in this thesis, functional response differences might act as 
reliable biomarkers for individual treatment response prediction. It should be noted that even 
though the sample sizes are quite small in the aripiprazole groups, there seems to be a valid 
difference between responders and non-responders. However, due to the study design it is not 
possible to definitely identify the factors responsible for the discrepancy in the functional 




In the next step, the SVM algorithm could differentiate between responders and non-
responders based on deactivations but not activations. It can be hypothesized that functional 
changes in the DMN might be associated with different treatment responses. Further 
experiments will be needed to define the specificity of the deactivations in these brain regions. 
It is not clear whether these deactivations are reward- related or might appear independently 
of different context stimuli. Furthermore, regions of the DMN need to be further explored.   
The SVM results predicted on the basis of the deactivation DRD parameter estimates with a 
balanced accuracy of 84.5% the treatment success of aripiprazole. In consequence, a 
translation of this result into the clinical setting could potentially predict in four out of five 
patients whether they would benefit from aripiprazole treatment or not. This would offer an 
enormous advantage over the current approach to drug administration. A look at the recent 
literature reveals that the rising call for personalized medicine, i.e. individually tailored 
treatment (Fernandes et al., 2020; Fountoulakis and Stahl, 2020; Lenze et al., 2020), also 
includes the application of treatment response prediction methods (reviewed in Kang and Cho, 
2020; reviewed in Zhang et al., 2020). In recent years clinical data, genetic features and other 
information such as electrophysiological data has been used to predict the treatment outcome 
of psychiatric patients. However, only a minority of studies have used neuroimaging results to 
estimate the success of the individual treatment of schizophrenia and bipolar patients. One of 
them was a proof-of-principle study using a linguistic machine learning system and fMRI data 
to predict lithium response of first-episode bipolar patients (Fleck et al., 2017). They were able 
to reach 80% accuracy in validation of symptom decrease after the treatment (Fleck et al., 
2017). Another study tried to predict the response to haloperidol in schizophrenia patients. 
They could show that striatal D2 occupancy predicted antipsychotic response as well as side 
effects of haloperidol (Kapur et al., 2000). In major depressive disorder research, neuroimaging 
has been used more often to find biomarkers that predict treatment response (Kozel et al., 
2011; McGrath et al., 2013). One of these studies used structural MRI data and applied an SVM 
classifier to predict clinical outcome (Gong et al., 2011). Their results demonstrated that grey 
matter as well as white matter could potentially forecast treatment success (Gong et al., 2011). 
Additionally, SVM algorithms applied to neuroimaging data have been used to predict response 
to behavioral therapy of various psychiatric or personality disorders (Ball et al., 2014; Mansson 
et al., 2015; Schmitgen et al., 2019). However, research of neuroimaging data being used as 
treatment response predictors is still limited. This was the first time a study used univariate 
results from a reward paradigm to predict treatment response by applying an SVM algorithm. 
Questions regarding the underlying pathomechanisms for different brain activation patterns 
between responders and non-responders still remain open and need to be examined in depth 
in the future.  
Taken together, the use of artificial intelligence, i.e. machine learning, might offer a great 




treatment. This, in turn, would lead to less trial-and-error drug administration and to a more 
efficient disease management.  
4.3   General discussion 
In this thesis, two fMRI studies examined differential pathophysiological processes of bipolar 
disorder and schizophrenia patients. Whereas in study A both diagnoses were compared 
categorically, study B used a transnosological approach to investigate the differential treatment 
responses. 
Previous studies reported partly opposing activation abnormalities in bipolar disorder and 
schizophrenia patients during the DRD paradigm (Richter et al., 2015; Trost et al., 2014). 
Whereas bipolar disorder patients demonstrated hypoactivations (Trost et al., 2014), 
schizophrenia patients presented hyperactivations in comparison to healthy controls (Richter 
et al., 2015). The hypo- and hyperactivations were both located in the same brain area, i.e. the 
frontal lobe. Therefore, pathophysiologies seem to be located in similar brain regions in 
schizophrenia and bipolar patients. However, the direction of their activation differed in the 
two diseases. In addition, a study by Melcher et al. (2014) revealed differences in the behavioral 
data, i.e. performance and reaction times, between the schizophrenia and bipolar disorder 
spectrum in the combined oddball-incongruence paradigm in an independent sample. These 
prior results suggested subgroup-specific differences in the pathomechanisms of the two 
disorders and urged for a closer examination. This thesis aimed to further elaborate these 
subgroup-specific differences.  
Study A found brain regions that were activated to varying degrees by alleged subgroups of the 
schizophrenia and bipolar disorder spectrum. The results show that specific pathophysiological 
processes, which can be addressed by the combined oddball-incongruence task, appear 
significantly more often in bipolar than schizophrenia patients. However, these group 
differences do not inevitably confirm diagnostic, categorical entities. On single case levels these 
effects might not be valid. It is important to note that diagnostic entities often limit the 
assertions of psychiatric studies. Therefore, more and more studies use a transnosological 
approach. Consequently, in the second part of this thesis a pilot study was conducted to 
retrospectively examine differential treatment response of bipolar and schizophrenia patients 
to different treatment arms. The results of study B indicate a biomarker for non-response to 
the dopaminergic partial agonist aripiprazole. The study revealed deactivations induced by the 
DRD paradigm, which were able to predict treatment response through the application of SVM 
algorithms. Additionally, activation in the NAc and avPFC can directly be associated with the 
DRD paradigm suggesting these brain areas to act as potential biomarkers. However, on a single 
case level it was not possible to divide responders from non-responders by applying these brain 




In recent years the strict nosological division between bipolar disorder and schizophrenia once 
established by Kraepelin, started to soften towards a continuum between the two disorders. 
Continuously, new findings were published, demonstrating concordance of genetic, biological 
and phenomenological properties (Chan et al., 2019; reviewed in Craddock et al., 2006; 
Keshavan et al., 2011; reviewed in Pearlson, 2015; Purcell et al., 2009; Ruocco et al., 2014; 
Tamminga et al., 2013; reviewed in Whalley et al., 2012). In consequence, a broad field 
emerged examining overlaps and differences between the two disorders. Various studies 
investigated cognition (Ancin et al., 2013; reviewed in Bora and Pantelis, 2015; Hill et al., 2013; 
Krishnadas et al., 2014; Lewandowski et al., 2014; Schretlen et al., 2013; Smith et al., 2009; Van 
Rheenen et al., 2016; reviewed in Wang et al., 2013), brain structure (Anderson et al., 2013; 
reviewed in De Peri et al., 2012; Haukvik et al., 2015; Mathew et al., 2014; Molina et al., 2011; 
Nanda et al., 2014; Rimol et al., 2010; Womer et al., 2014) and function (Costafreda et al., 2011; 
Lui et al., 2015) in comparative settings to understand the relation and pathophysiology of both 
disorders. Since some of the studies reported contradictory results, it is important to further 
examine and strive for a greater understanding of neurobiological pathomechanisms 
influencing the effects of bipolar disorder and schizophrenia. Future experiments hence ought 
to follow the idea of the Research Domain Criteria (RDoC) Initiative to perceive psychiatric 
disorders, in particular schizophrenia and bipolar disorder, as spectrums and preferably work 
with dimensions of detectable neurobiological and behavioral features (Insel et al., 2010). In 
study A schizophrenia patients displayed similar, but low-threshold effects compared to bipolar 
disorders. Therefore, a better approach might be to categorize the groups according to 
biological or behavioral features rather than solely their respective diagnosis. A multimodal 
approach of neuroimaging data involving results from tasks eliciting different cognitive or 
emotional pathways, might improve the understanding of causes for the partly overlapping 
symptomatology.  
The ultimate goal connecting both studies is the importance and relevance to improve the 
current status quo of psychiatric treatment. A recent study by Wolfers et al. (2018) examined 
a great sample of bipolar and schizophrenia patients’ brain structures and concluded that an 
average patient does not exist. They reported massive interindividual differences and an 
overlap of more than two percent in only a few brain loci (Wolfers et al., 2018). Therefore, a 
deeper understanding of the deficits in the reward and attention system as well as alterations 
in the DMN of bipolar disorder and schizophrenia might eventually make it possible to treat 
psychiatric disorders more specifically or even individually customized to the respective 
patients’ needs and impairments. Personalized psychiatric treatment would give patients the 




4.4   Limitations and Outlook 
Study A revealed convincing indications for aberrant activations of the frontoparietal networks 
of bipolar and schizophrenia patients depending on the difficulty of attentional tasks. However, 
the study also faced some limitations. First, the sample sizes of the patient groups and healthy 
individuals varied a lot. In future studies the different groups should consist of similar sample 
sizes to avoid undesirable influences on the effect size. Furthermore, the patients participating 
in this study received different psychopharmacological medication. On the one hand, this 
mirrors a naturalistic setting as both disorders realistically present a very heterogeneous clinical 
picture with often more than one psychopharmacological drug. On the other hand, to exclude 
possible effects of medication on the performance and brain activation of the patients, it would 
be better to include either medication-naïve or monotherapeutically treated patients 
(preferably with the same psychopharmacological agent). Another limitation of this study might 
be that the conditions, oddball and incongruence deviate from “typical” oddball and 
incongruence tasks. As they, in contrast to classical oddball and incongruence experiments, 
contain two dimensions, it is possible that bottom-up and top-down processes take place 
concurrently. As a consequence, the cognitive control processes as well as stimulus-driven 
bottom-up processes would both be depicted in the results and it would not be possible to 
distinguish them. Lastly, the patients’ ages differed, i.e. schizophrenia patients were on average 
younger than the bipolar patients. This is no surprise as the chance of chronification in 
schizophrenia patients increases with proceeding age. Bipolar patients, though, commonly 
keep a quite constant level of cognitive performance over the years. Therefore, oftentimes 
younger schizophrenia patients are included into studies as they are still able to handle the 
challenges of the oftentimes demanding study designs. To make sure that age had no impact 
on the results described in the previous chapters, the univariate fMRI analyses were repeated 
with the covariate age. The results did not display any major differences compared to the prior 
results. It can be concluded that even though the mean age differed between the two patient 
groups, the resulting effects originated from valid psychopathological anomalies. 
It is important to note that study B was a small estimated pilot study in order to look for 
potential effects and does not replace the necessity of a large-scale clinical study. The sample 
sizes were very small; hence, all results need to be revised carefully. However, even though the 
sample sizes were very small in the different treatment response groups, significant differences 
between the responder and non-responder aripiprazole group could be detected. An 
examination of the raw data revealed that the differences were not attributable to one single 
outlier, but rather the quite homogeneous non-responder group. This gives a first hint of 
potential underlying differences in neural networks and processing of this treatment group but 
must be further elaborated to get to the bottom of this effect. Furthermore, an objective 
response criterion must be implemented. Other studies have used independent scores of e.g. 




would give an opportunity to better understand the origin of activation differences. Another 
important improvement would be to only compare monotherapeutically treated patients. A 
mix or wide range of antipsychotic, antidepressant etc. administration makes it hard to 
determine which drug was responsible for the treatment success. However, it is also important 
to mention that unmedicated schizophrenia and bipolar patients can often not be recruited for 
clinical studies as the severity of their symptoms would not make it possible to complete the 
demanding fMRI tasks. Taken together, future studies trying to identify biomarker for 
treatment response should ideally strive for the following key aspects in their study design: 
1) Baseline measurement of clinical state on the basis of objective psychopathological 
scales such as PANSS, CGI, MADRS etc.  
2) Monotherapeutic treatment with either an atypical or typical antipsychotic or 
aripiprazole  
3) Assignment to the responder or non-responder group on the basis of cut-off values of 
psychopathological scores 
However, due to the difficulties of thoroughly implementing such a complex and challenging 
study design, not many studies developing strategies for treatment prediction have been 
published, yet. Nevertheless, the realization of a similar but larger study has great potential to 
identify biomarkers that predict individual treatment response in psychiatric patients.  
Taking everything into account, both studies found exclusive results in fields that have not yet 
been extensively researched. On the one hand, this thesis could provide some interesting novel 
insights into cognitive control processes of bipolar and schizophrenia patients. The presented 
results and their interpretation suggest some kind of balanced cognitive control system that 
destabilizes when too much mental load is expected. Future studies will need to replicate these 
findings in an independent sample and try to identify the underlying neural correlates in more 
detail. Treatment response prediction using neuroimaging data, on the other hand, will 
probably be explored much more in the following years. The technical usage of artificial 
intelligence, i.e. SVM algorithms, is booming in biotechnological areas and will ultimately also 
be applied to neuroimaging data. It yields great opportunities for personalized psychiatric 







5.1   Summary 
Psychiatric disorders, in particular schizophrenia and bipolar disorder, affect the patients’ lives 
deeply on many levels and place a heavy burden on the healthcare system. The treatment of 
these diseases is often complicated and marked by many setbacks. Symptoms that have the 
strongest consequences for coping with everyday life are the impairments of cognitive 
performance, for example memory or attention deficits. Therefore, it is of great interest to 
better understand the underlying pathomechanisms to eventually improve treatment options 
for those patients. In this thesis two different fMRI studies were used to investigate the 
functional correlates of patients suffering from schizophrenia or bipolar disorder while 
performing a combined oddball-incongruence task and a reward associated task. 
Study A conducted a categorical comparison between bipolar and schizophrenia patients of the 
brain activation during an oddball and incongruence task. The results showed 
pathophysiological differences in the activation intensities between bipolar and schizophrenia 
patients as well as between the patient groups and healthy individuals. Overall it seems as if 
the brain activation severely depended on the task difficulty leading to compensatory 
hyperactivations in frontal brain areas of bipolar patients during the oddball task. Schizophrenia 
patients demonstrated low threshold hyperactivations in the intraparietal cortex compared to 
healthy controls. In the cognitively more demanding incongruence condition these 
compensatory mechanisms seemed to fail leading to hypoactivations in various brain regions 
such as the middle frontal gyrus or ventral pathway.  
Pilot study B searched retrospectively for functional markers which enable support vector 
machine algorithms predicting specific treatment response to typical and atypical 
antipsychotics as well as aripiprazole in a transnosological sample consisting of bipolar and 
schizophrenia patients. Consequently, (de-)activation differences between responders and 
non-responders in their respective treatment arm resulting from the desire-reason-dilemma 
paradigm were applied to support vector machine algorithms. The implementation of 
parameter estimates from deactivations of aripiprazole non-responders in brain regions 
partially associated with the default mode network, led to a successful treatment response 
prediction of patients receiving aripiprazole.  
Even though in future studies the sample sizes should be increased and monotherapeutical 
treatment ensured, this thesis already provides important insights on the pathomechanisms of 
bipolar disorder and schizophrenia patients or more specifically within the spectrum of both 
diseases. Prospectively, further studies can help to specify potential functional biomarkers 
which also might be able to predict treatment response and consequently approach 








5.2   Zusammenfassung 
Psychiatrische Erkrankungen, insbesondere Schizophrenie und bipolare Störung, haben 
schwerwiegende Auswirkungen auf das Leben der Betroffenen und stellen eine große 
Belastung für das Gesundheitssystem dar. Die Behandlung dieser Krankheiten ist oftmals 
kompliziert und von häufigen Rückschlägen geprägt. Symptome, die besonders starke 
Konsequenzen auf die Bewältigung des Alltags der Erkrankten haben, sind verschiedene 
Beeinträchtigungen der kognitiven Leistung, wie z.B. des Gedächtnisses und der 
Aufmerksamkeit. Aus diesem Grund ist es von großem Interesse, die Ursachen der 
zugrundeliegenden Pathomechanismen genauer zu verstehen, um gegebenenfalls die 
Behandlungsmöglichkeiten zu verbessern. In dieser Dissertation wurden mittels zwei 
verschiedener funktioneller Magnetresonanztomographiestudien die funktionellen Korrelate 
von Patientinnen und Patienten, die an Schizophrenie oder bipolarer Störung erkrankt sind, 
während sie eine kombinierte Oddball-Inkongruenz-Aufgabe und eine belohnungsassoziierte 
Aufgabe bearbeiten, genauer untersucht.  
In Studie A fand ein kategorischer Vergleich der Gehirnaktivierung zwischen bipolaren und 
schizophrenen Patientinnen und Patienten, sowie gesunden Kontrollen, während des Oddball- 
und Inkongruenzeffekts statt. Die Ergebnisse zeigten pathophysiologische Unterschiede in der 
Intensität der Aktivierungen bei den bipolaren im Vergleich zu den schizophrenen Patientinnen 
und Patienten, als auch zwischen den Erkrankungsgruppen und der gesunden Kontrollgruppe. 
Insgesamt scheinen die Gehirnaktivierungen stark von der Aufgabenschwierigkeit abzuhängen, 
sodass bipolare Patientinnen und Patienten in der leichteren Oddball-Aufgabe potentielle 
kognitive Defizite mit teils diagnose-spezifischen Hyperaktivierungen im frontalen Bereich 
kompensieren konnten. Schizophrene Probandinnen und Probanden zeigten hier nur leichte 
Hyperaktivierungen im intraparietalen Kortex im Vergleich zu den gesunden Kontrollen. In der 
schwierigeren Inkongruenz-Aufgabe schienen die Kompensationsmechanismen zu versagen, 
sodass nun diagnose-unspezifische Hypoaktivierungen in zahlreichen, u.a. auch frontalen, 
Hirnarealen der beiden Erkrankungsgruppen auftraten.  
In Studie B wurden pilotierend retrospektiv funktionelle Marker gesucht, mit denen Support 
Vector Machine-Analysen das differentielle Ansprechen auf typische und atypische 
Antipsychotika sowie Aripiprazol von schizophrenen und bipolaren Individuen in einer 
transnosologischen Stichprobe vorhersagen können. Dabei wurden (De-) 
Aktivierungsunterschiede zwischen Respondern und Nicht-Respondern der jeweiligen 
Psychopharmakagruppen im Desire-Reason-Dilemma-Paradigma verglichen und für die 
Auswertung mit Support Vector Machine-Algorithmen genutzt. Unter Verwendung der 
Intensitätswerte von Deaktivierungen in Hirnarealen der Aripiprazol Non-Responder, die unter 
anderem mit dem Default Mode Network assoziiert zu sein scheinen, war es möglich den 




Auch wenn in zukünftigen Studien die Stichprobengröße erhöht und eine monotherapeutische 
psychopharmakologische Behandlung der Patienten gewährleistet werden sollte, liefert diese 
Doktorarbeit wichtige Erkenntnisse über die Pathomechanismen in Patienten mit bipolarer 
Störung oder Schizophrenie – beziehungsweise innerhalb des Spektrums beider Erkrankungen. 
Zukünftig können weitere Studien helfen, potentielle funktionelle Marker zur Vorhersage des 
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7 EIGENANTEIL AN DATENERHEBUNG UND DATENAUSWERTUNG UND EIGENE 
VERÖFFENTLICHUNGEN 
Im Rahmen meiner Promotion habe ich Verhaltensdaten, sowie Daten aus der funktionellen 
Magnetresonanztomographie von über 80 Patientinnen und Patienten für die laufenden vom 
BMBF bzw. der DFG geförderten Projekte BipoLife B2 und Psycourse Teilprojekt 2 Workpackage 
1 erhoben und analysiert. Für die Doktorarbeit habe ich auf bereits zuvor von anderen 
Mitarbeiterinnen (Dr. Sarah Trost und Alexandra Petrovic) erhobene Daten zurückgegriffen, 
deren Analysen jedoch selbstständig geplant und durchgeführt. Diese Arbeit verwendete für 
die Auswertung Daten aus langfristig angelegten Projekten von Herrn Professor Grubers 
Professur in Göttingen, insbesondere aus DFG-geförderten Projekten innerhalb der KFO241 
sowie aus parallellaufenden, nicht Drittmittel-geförderten Projekten. Die Auswertungen 
bezüglich der Differenzierung von Aufmerksamkeitsnetzwerken bipolarer im Vergleich zu 
schizophrenen Patienten und gesunden Kontrollen während einer kombinierten Oddball-
Inkongruenz-Aufgabe wurden vollständig von mir durchgeführt und sind eins der beiden 
zentralen Ergebnisse dieser Dissertationen. Die univariaten Auswertungen bezüglich der 
Vorhersage der Therapieprädiktion von bipolaren und schizophrenen Patienten anhand von 
funktionellen MRT- Aktivierungen induziert durch das DRD Paradigma wurden vollständig von 
mir durchgeführt und lieferten die Grundlage der folgenden Support Vector Machine-Analysen. 
Diese wurden von Herrn Dr. Evgeny Gladilin durchgeführt und sind in Kapitel 3.3 zu finden. Die 
wissenschaftliche Einordnung, Interpretation und Diskussion aller Daten wurden von mir 
übernommen.  
Teilergebnisse der vorliegenden Arbeit wurden in folgendem Aufsatz zur Publikation 
eingereicht: 
Rauer, L., Trost, S., Petrovic, A., Gruber, O. (2020) Cortical activation abnormalities in bipolar 
and schizophrenia patients in a combined oddball-incongruence paradigm. Eur Arch Psychiatry 
Clin Neurosci, Epub ahead of print, doi: 10.1007/s00406-020-01168-1  
Diese Publikation basiert auf den Ergebnissen aus den Dissertationskapiteln 3.1.1 und 3.2.1. 
Auch die Diskussion der potentiell unterliegenden Pathophysiologien der beiden 
Patientengruppen während der Aufmerksamkeitsaufgabe wurde in dieser Publikation inhaltlich 
abgebildet (s. Kapitel 4.1). Mein Eigenanteil an der Publikation erstreckt sich auf die 
Qualitätskontrolle, Analyse und Auswertung der Daten bezüglich des Oddball- und 
Inkongruenzeffekts, der Interpretation der Ergebnisse und das Schreiben des Manuskripts, 







1. Bei der eingereichten Dissertation zum Thema „Examinations of pathomechanisms in 
schizophrenic and bipolar disorders – results from two functional magnetic resonance 
imaging studies“ handelt es sich um meine eigenständig erbrachte Leistung. 
2. Ich habe nur die angegebenen Quellen und Hilfsmittel benutzt und mich keiner 
unzulässigen Hilfe Dritter bedient. Insbesondere habe ich wörtlich oder sinngemäß aus 
anderen Werken übernommene Inhalte als solche kenntlich gemacht. 
3. Die Arbeit oder Teile davon habe ich bislang nicht an einer Hochschule des In- oder 
Auslands als Bestandteil einer Prüfungs- oder Qualifikationsleistung vorgelegt. 
4. Die Richtigkeit der vorstehenden Erklärungen bestätige ich. 
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